<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Risks associated with epilepsy during pregnancy and the postpartum period</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Risks associated with epilepsy during pregnancy and the postpartum period</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Risks associated with epilepsy during pregnancy and the postpartum period</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Elizabeth E Gerard, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Thomas McElrath, MD, PhD</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Steven C Schachter, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Charles J Lockwood, MD, MHCM</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">John F Dashe, MD, PhD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jan 29, 2024.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>While most pregnancies in women with epilepsy are uncomplicated, the risk for some perinatal complications may be increased compared with the general population. Offspring are at increased risk for major congenital malformations and adverse neurodevelopmental outcomes. However, many potential risks can be mitigated with informed antiseizure medication (ASM) choice and management, and, for many women with epilepsy, risks are not much greater than in the general population.</p><p>This topic will discuss the risks associated with epilepsy and pregnancy. The management of pregnancy in women with epilepsy is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/2224.html" rel="external">"Management of epilepsy during preconception, pregnancy, and the postpartum period"</a>.)</p><p class="headingAnchor" id="H2"><span class="h1">MORBIDITY AND MORTALITY</span></p><p class="headingAnchor" id="H2550334747"><span class="h2">Obstetric complications</span><span class="headingEndMark"> — </span>Studies of pregnancy complications in women with epilepsy have shown mixed results, with a tendency towards a small but increased risk of obstetric complications in this population [<a href="#rid1">1-13</a>]. A meta-analysis found that compared with pregnant women without epilepsy, pregnant women with epilepsy had an increased risk of cesarean delivery, induced labor, preterm birth, gestational diabetes, pre-eclampsia, intrauterine growth restriction, placental abruption, and stillbirth [<a href="#rid12">12</a>]. These complications were increased in pregnant women with epilepsy regardless of whether they were taking antiseizure medications (ASMs); the magnitude of the effect for these complications ranged from 1.11 to 1.89 in pooled odds ratios [<a href="#rid12">12</a>].</p><p class="headingAnchor" id="H2698952225"><span class="h2">Maternal mortality</span><span class="headingEndMark"> — </span>A few studies have found that mortality rates during pregnancy are increased for pregnant women with epilepsy compared with the general population of pregnant women [<a href="#rid3">3,12,14,15</a>]. Since maternal mortality is a rare event, this translates to a low absolute increase in risk of less than 0.1 percent. In a meta-analysis based upon four available observational studies, the incidence of maternal death in pregnant women with epilepsy was 0.077 percent, which was higher than the incidence in unaffected pregnant women (0.0085 percent). The unadjusted pooled odds ratio (OR) for maternal mortality was 5, with very wide confidence intervals, but the risk difference between groups was not measurable (unadjusted OR 5.00, 95% CI 1.38-18.04; risk difference [RD] 0.00, 95% CI 0 to 0 percent) [<a href="#rid12">12</a>]. One of the four studies contributed 88 percent of the patients and thus was primarily responsible for this finding; patients in this study were identified based on hospital diagnosis codes, which precluded confirmation of the epilepsy diagnosis or etiology [<a href="#rid3">3</a>]. These studies did not have a comparison group of nonpregnant patients with epilepsy. Thus, it is not clear if the possible increased risk is specifically related to pregnancy.</p><p>There are several possible explanations for increased maternal mortality among pregnant women with epilepsy in these reports, including an increase in medical comorbidities, an increase in life-threatening complications of pregnancy, and an increase in seizure-related complications, including sudden unexpected death in epilepsy (SUDEP). In one study of epilepsy-related deaths in a United Kingdom population-based registry, 11 out of 14 deaths (79 percent) were attributed to SUDEP; approximately one-third occurred during the postpartum period [<a href="#rid15">15</a>]. Two-thirds of the deaths were in patients treated with <a class="drug drug_general" data-topicid="9545" href="/z/d/drug information/9545.html" rel="external">lamotrigine</a> (a possible risk factor for SUDEP in females). However, since lamotrigine is the most frequently prescribed medication in this population, it is not clear if this was merely a reflection of prescribing practices. It is also possibly related to the substantial lowering of lamotrigine concentrations that occur during pregnancy if doses are not adjusted. (See  <a class="medical medical_review" href="/z/d/html/2224.html" rel="external">"Management of epilepsy during preconception, pregnancy, and the postpartum period"</a>.)</p><p>SUDEP is discussed in more detail separately. (See  <a class="medical medical_review" href="/z/d/html/2215.html" rel="external">"Sudden unexpected death in epilepsy"</a>.)</p><p class="headingAnchor" id="H205070775"><span class="h2">Fetal death or stillbirth</span><span class="headingEndMark"> — </span>There may be an increase in the risk of fetal death or stillbirth among offspring of individuals with epilepsy. Both a 2023 systematic review and meta-analysis [<a href="#rid12">12</a>] and a large population-based retrospective cohort study of delivery in United States hospitals between 2007 and 2011 [<a href="#rid3">3</a>] found a small increased risk of miscarriage or stillbirth. In the meta-analysis, stillbirth was more frequent among pregnant women with epilepsy compared with pregnant women without epilepsy (0.86 versus 0.60 percent, unadjusted OR 1.37, 95% CI 1.29-1.47, RD 0.0 percent, 95% CI 0 to 0 percent) [<a href="#rid12">12</a>]. Similarly, In the United States study, the risk of stillbirth was higher for pregnant women with epilepsy compared with women without epilepsy (0.8 versus 0.6 percent, adjusted OR 1.27, 95% CI 1.17-1.38), but the absolute increase in risk was only 0.2 percent [<a href="#rid3">3</a>].</p><p>Reports of miscarriage rates have varied by study and are subject to ascertainment bias. However, in a prospective observational study at four United States academic medical centers, miscarriage rates in the women with epilepsy were the same as in control women who were recruited prior to pregnancy [<a href="#rid16">16</a>].</p><p>The mechanism of an increased risk of fetal death among pregnant women with epilepsy is also not well understood. In a large European registry, only 1 of 165 reported miscarriages or stillbirths was associated with seizures or status epilepticus (SE); two-thirds of these pregnancies were seizure free [<a href="#rid17">17</a>]. Whether ASM exposure contributes to risk of spontaneous miscarriage is uncertain, but in aggregate the contribution appears to be minimal [<a href="#rid1">1</a>]. In a large population-based observational study that included nearly one million pregnancies, use of ASMs during pregnancy conferred a slightly higher risk of spontaneous abortion compared with not using ASMs (adjusted risk ratio [aRR] 1.13, 95% CI 1.04-1.24); however, when limited to women with an epilepsy diagnosis, the use of ASMs was not associated with increased risk (aRR 0.98, 95% CI 0.87-1.09) [<a href="#rid18">18</a>].</p><p class="headingAnchor" id="H1819917410"><span class="h2">Preterm birth</span><span class="headingEndMark"> — </span>ASM exposure is associated with an increased risk of preterm birth [<a href="#rid12">12,19</a>]. Interestingly, the effect was also present among females prescribed ASMs for a psychiatric indication, suggesting that the effect may be medication associated [<a href="#rid19">19</a>]. These results are similar to those of an earlier national registry of 679,762 Danish singleton births, of which 2982 were exposed to ASMs [<a href="#rid20">20</a>]. In this cohort, however, the risk of prematurity was limited to those without a history of epilepsy. In the 2023 meta-analysis, preterm birth was increased in pregnant women with epilepsy compared with pregnant women without epilepsy (10.5 versus 7.2 percent, OR 1.41, 95% CI 1.32-1.51; RD 2 percent, 95% CI 1 to 3 percent) [<a href="#rid12">12</a>].</p><p class="headingAnchor" id="H1413747599"><span class="h2">Cesarean delivery</span><span class="headingEndMark"> — </span>Most experts agree that epilepsy alone is not an indication for cesarean delivery [<a href="#rid13">13</a>]. However, pregnant women with epilepsy may be more likely to be delivered by cesarean. In the 2023 meta-analysis, cesarean delivery was more common among pregnant women with epilepsy compared with pregnant individuals without epilepsy (36.9 versus 31.6 percent, pooled OR 1.54, 95% CI 1.43-1.65; RD 8 percent, 95% CI 6 to 9 percent) [<a href="#rid12">12</a>].</p><p>Mode of delivery may depend on provider preference, however. In the prospective Maternal Outcome of Antiepileptic Drugs (MONEAD) study, pregnant subjects with epilepsy were not more likely than control pregnant subjects to be delivered by cesarean [<a href="#rid21">21</a>]. The likelihood of cesarean delivery without a trial of labor was the same in pregnant women with epilepsy and controls if they delivered at a tertiary care center. However, outside of the recruitment centers, women with epilepsy were more than twice as likely as pregnant controls to have a cesarean section without a trial of labor.</p><p class="headingAnchor" id="H2473778968"><span class="h2">Other outcomes</span><span class="headingEndMark"> — </span>Epilepsy is also associated with a small but significant increase in risk for several other perinatal outcomes. In a 2023 systematic review and meta-analysis of 76 studies, risk was moderately higher among women with epilepsy compared with women without epilepsy, for the following outcomes [<a href="#rid12">12</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Pre-eclampsia – 6.8 versus 5.2 percent (OR 1.36, 95% CI 1.05-1.77; RD 1 percent, 95% CI 0 to 3 percent)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Antepartum hemorrhage – 2.2 versus 1.6 percent (OR 1.38, 95% CI 1.32-1.45; RD 0 percent, 95% CI 0 to 1 percent)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Small for gestational age (SGA) – 7.7 versus 4.6 percent (OR 1.38, 95% CI 1.22-1.55; RD 2 percent, 95% CI 1 to 3 percent)</p><p></p><p class="headingAnchor" id="H3862215553"><span class="h2">Effect of seizures on the fetus</span><span class="headingEndMark"> — </span>In addition to concerns about fetal exposure to ASMs, there are risks to the fetus from maternal seizures. In particular, generalized tonic-clonic seizures can lead to hypoxia and lactic acidosis, which may harm the fetus via placental transfer [<a href="#rid13">13</a>]. Although probably less harmful, other types of seizures may increase the risk of fetal growth restriction, fetal injury, and premature delivery. However, few studies have evaluated the direct effects of maternal seizures on the fetus.</p><p>Fetal hypoxia may occur because of maternal hypoxia or decreased placental blood flow, but no information is available on the number or length of seizures that may jeopardize the fetus. One report of fetal heart rate monitoring during a maternal generalized tonic-clonic seizure lasting 2.5 minutes revealed significant fetal heart rate deceleration lasting up to 30 minutes after the seizure [<a href="#rid22">22</a>]. While nonconvulsive seizures are believed to be less dangerous [<a href="#rid13">13</a>], another case report documented significant fetal bradycardia during a one-minute, focal impaired awareness seizure (also called complex partial seizure) [<a href="#rid23">23</a>].</p><p>Other risks of maternal seizures include injury to the fetus, placental abruption, or fetal loss due to maternal trauma sustained during a seizure.</p><p>In a population-based data set in Taiwan, compared with women with epilepsy who did not suffer seizures during pregnancy, epileptic seizures during pregnancy were marginally associated with SGA infants (adjusted OR 1.34, 95% CI 1.01-1.84) but not with preterm birth (OR 1.12, 95% CI 0.73-1.71) [<a href="#rid24">24</a>]. Of note, seizures during pregnancy in this study were defined as presenting to a hospital or emergency department with seizures, which may have selected for more severe seizure types. A study of 249 children in the United Kingdom found that the number of generalized tonic-clonic convulsive seizures during pregnancy was a negative predictor of verbal intelligence quotient (IQ) in the children; in particular, the occurrence of five or more convulsive seizures during pregnancy was associated with developmental delay [<a href="#rid25">25</a>].</p><p>In a large European registry of 1956 pregnancies in 1882 women with epilepsy, SE occurred in 1.8 percent, one-third of which were convulsive type [<a href="#rid17">17</a>]. Only one case of SE was associated with stillbirth; the remaining cases were not clearly associated with fetal or maternal complications.</p><p class="headingAnchor" id="H6473478"><span class="h1">EFFECT OF PREGNANCY ON SEIZURES</span></p><p class="headingAnchor" id="H1957671535"><span class="h2">Seizure control</span><span class="headingEndMark"> — </span>The effect of pregnancy and antiseizure medications (ASMs) management on seizure control is reviewed in the following sections.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Evidence of seizure worsening during pregnancy</strong> – Although there is variability in the published literature, most earlier studies reported that 20 to 50 percent of women have worsening of seizures during pregnancy compared with their baseline [<a href="#rid7">7,26-31</a>]. The 2006 International Registry of Antiepileptic Drugs and Pregnancy (EURAP) also reported on seizure control in pregnancy, but the comparator was the first trimester rather than the nonpregnant baseline [<a href="#rid17">17</a>]. Among 1956 pregnancies in 1882 women with epilepsy, seizure frequency and ASM treatment remained unchanged in 62 to 64 percent; 59 percent were seizure free during pregnancy; only 17 percent reported increased seizure frequency. Status epilepticus (SE) occurred in approximately 2 percent, one-third of which were convulsive type. A 2019 systematic review of the literature from the International League Against Epilepsy (ILAE) Task Force on Women and Pregnancy concluded that approximately two-thirds of women with epilepsy maintain baseline seizure control during pregnancy [<a href="#rid13">13</a>]. However, none of these studies compared seizure frequency among pregnant women with the gold standard of seizure frequency among nonpregnant women with epilepsy followed over the same length of time and in the same manner; therefore, the evidence was insufficient to determine the change in seizure frequency for pregnant women with epilepsy [<a href="#rid7">7</a>]. A 2020 report from the Maternal Outcomes and Neurodevelopmental Effects of Antiepileptic Drugs (MONEAD) Study Group did this and found that pregnancy did not alter seizure frequency in a prospective more recent cohort [<a href="#rid32">32</a>]. The apparent increase in seizures seen in past studies may have been due, at least in part, to lack of awareness of increased ASM metabolism during pregnancy when those studies were conducted. (See  <a class="medical medical_review" href="/z/d/html/2224.html" rel="external">"Management of epilepsy during preconception, pregnancy, and the postpartum period", section on 'Antiseizure medication monitoring and dose adjustment'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Prevention of seizure worsening during pregnancy</strong> – In the context of meticulous ASM management with therapeutic drug monitoring during pregnancy, seizure frequency does not seem to increase during pregnancy. Supporting evidence is provided by a 2020 prospective observational study from the MONEAD Study Group, which compared the proportion of women with increased seizure frequency during pregnancy with a matched, nonpregnant control group followed for the same length of time and with the same protocol [<a href="#rid32">32</a>]. The main analysis included 299 pregnant women and 93 controls who had a history of seizures that impaired awareness. Seizure frequency was higher during pregnancy than in an individual woman's nongravid baseline in 23 percent of pregnant women compared with 25 percent of controls during the corresponding time epochs (OR 0.93, 95% CI 0.54-1.60). In other words, the risk of seizure increase over two similar time periods was the same in both pregnant and nonpregnant women with epilepsy. However, the two groups differed in medication management. The ASM dose was changed at least once in 74 percent of the pregnant women compared with only 31 percent of the controls (OR 6.36, 95% CI 3.82-10.59). Moreover, doses of individual ASMs were increased during pregnancy in alignment with reported alterations in the clearance of that ASM during pregnancy, and doses were decreased again after delivery. These findings will help clinicians to counsel women with epilepsy on expectations for seizure control during pregnancy. (See  <a class="medical medical_review" href="/z/d/html/2224.html" rel="external">"Management of epilepsy during preconception, pregnancy, and the postpartum period", section on 'Counseling'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Seizures during the peripartum period</strong> – Seizures may be more likely to occur during the peripartum period. A study of women enrolled in the Kerala Registry of Epilepsy and Pregnancy in India found that seizure relapse was the highest during the three peripartum days (one day prior to one day after the day of delivery) [<a href="#rid31">31</a>]. EURAP reported that seizures occurred during delivery in 3.5 percent of the enrolled women, and one woman had convulsive SE [<a href="#rid17">17</a>]. In most cases, however, labor and delivery were not associated with increased complications.</p><p></p><p class="headingAnchor" id="H3160952017"><span class="h2">Predictors of seizure worsening</span><span class="headingEndMark"> — </span>The main risk factor for seizures during pregnancy is baseline seizure frequency before pregnancy; women who are seizure free in the nine months prior to pregnancy are less likely to have seizure worsening [<a href="#rid13">13,17,31,32</a>]. Other reported predictors are focal epilepsy syndromes [<a href="#rid13">13,17,31</a>], ASM type, polytherapy, patient adherence, and the use of therapeutic drug monitoring [<a href="#rid7">7,26-31,33,34</a>].</p><p>Some women who experience increased seizure frequency are sleep deprived or nonadherent with their medications because of concerns about the effects of the medication on the developing fetus [<a href="#rid13">13,35,36</a>]. Altered ASM pharmacokinetics also contribute to increased seizure frequency during pregnancy. (See  <a class="medical medical_review" href="/z/d/html/2224.html" rel="external">"Management of epilepsy during preconception, pregnancy, and the postpartum period", section on 'Antiseizure medication monitoring and dose adjustment'</a>.)</p><p class="headingAnchor" id="H6473713"><span class="h1">DEPRESSION AND ANXIETY</span><span class="headingEndMark"> — </span>Individuals with epilepsy have an increased prevalence of comorbid depression and anxiety symptoms compared with individuals without epilepsy, and this appears to be true during pregnancy and the postpartum period as well.</p><p>Detection of depression and anxiety during pregnancy and the postpartum period is important because both pharmacologic and nonpharmacologic treatments are available, and untreated illness may have consequences for both mother and child. Several studies have suggested that females with epilepsy may be undertreated for depression compared with females without epilepsy [<a href="#rid37">37,38</a>], emphasizing the importance of screening and appropriate treatment. (See  <a class="medical medical_review" href="/z/d/html/114559.html" rel="external">"Comorbidities and complications of epilepsy in adults", section on 'Depression and anxiety'</a> and  <a class="medical medical_review" href="/z/d/html/1718.html" rel="external">"Unipolar major depression during pregnancy: Epidemiology, clinical features, assessment, and diagnosis", section on 'Potential adverse outcomes'</a> and  <a class="medical medical_review" href="/z/d/html/108261.html" rel="external">"Mild to moderate episodes of antenatal unipolar major depression: Choosing treatment"</a> and  <a class="medical medical_review" href="/z/d/html/1703.html" rel="external">"Severe antenatal unipolar major depression: Choosing treatment"</a>.)</p><p>In a population-based study that included 706 pregnancies in women with epilepsy and over 100,000 pregnancies in controls without epilepsy, peripartum depression affected 27 percent of those with epilepsy compared with 23 percent of those with other chronic diseases and 19 percent of the entire nonepilepsy population [<a href="#rid37">37</a>]. These rates were similar to those reported in a subsequent prospective single-center study [<a href="#rid39">39</a>]. Rates of anxiety were similarly elevated in women with epilepsy compared with all others (22 versus 15 percent) [<a href="#rid37">37</a>]. In the prospective Maternal Outcomes and Neurodevelopmental Effects of Antiepileptic Drugs (MONEAD) study, 7.3 percent of the pregnant participants with epilepsy met criteria for major depression during pregnancy or the postpartum period, as defined by the Structured Clinical Interview for Diagnostic and Statistical Manual of Mental Disorders-IV (SCID) [<a href="#rid40">40</a>]. Statistically, this did not differ from the incidence of major depression in control participants without epilepsy or nonpregnant controls with epilepsy. However, depressive symptoms, as measured by the Beck Depression Inventory II (BDI), were elevated in postpartum mothers with epilepsy when compared with control mothers. Anxiety symptoms, as measured by the Beck Anxiety Inventory (BAI), were elevated in individuals with epilepsy both during pregnancy and in the postpartum state when compared with pregnant controls. Additionally, compared with nonpregnant participants with epilepsy, pregnant participants had higher levels of depression during pregnancy and both depression and anxiety in the postpartum state. The authors draw attention to the importance of monitoring pregnant participants with epilepsy for anxiety and depressive symptoms. Anxiety was associated with suicidal ideation [<a href="#rid40">40</a>], and maternal anxiety has been linked to poorer neurodevelopmental outcomes [<a href="#rid41">41</a>].</p><p>These studies suggest that risk factors for depression or anxiety among women with epilepsy include ongoing seizures, history of physical and/or sexual abuse, adverse socioeconomic factors, multiparity, previous loss of a child, antiseizure medication (ASM) use (in particular polytherapy), unplanned pregnancy, and prepregnancy depression or anxiety [<a href="#rid37">37,39,40</a>].</p><p class="headingAnchor" id="H4"><span class="h1">EFFECTS OF ASMs ON THE FETUS AND CHILD</span><span class="headingEndMark"> — </span>The risks of major congenital malformations (MCMs) are the best-studied effects of in utero antiseizure medication (ASM) exposure. Congenital malformations are defects of organs or body parts, most often occurring due to a defect in embryonic development; malformations are considered major (ie, MCMs) when they have medical, surgical, and/or social implications. (See  <a class="medical medical_review" href="/z/d/html/110898.html" rel="external">"Congenital anomalies: Epidemiology, types, and patterns", section on 'Malformations'</a>.)</p><p>For some ASMs, the risks of MCMs are very well characterized thanks to several prospective and population-based registries, though data are lacking for many other ASMs. The risk of being born small for gestational age (SGA) is another fetal outcome that has meaningful data related to specific ASM exposure. Finally, some cohort studies have shed light on the effects of certain ASMs on child neurodevelopment. The ASM-specific risks will be summarized here.</p><p>Risks associated with ASM use during pregnancy can be minimized by preconception planning and careful management during pregnancy. Choosing ASM(s) with lower risks for the fetus and child and ensuring the lowest therapeutic dose is used during pregnancy can reduce potential risks. (See  <a class="medical medical_review" href="/z/d/html/2224.html" rel="external">"Management of epilepsy during preconception, pregnancy, and the postpartum period"</a>.)</p><p class="headingAnchor" id="H7523673"><span class="h2">Major congenital malformations and their risk factors</span><span class="headingEndMark"> — </span>When all ASMs are considered, the reported risk of MCMs with fetal exposure is 4 to 6 percent, compared with a population estimate of 2 to 3 percent [<a href="#rid26">26,42-46</a>]. The increased risk seems to be primarily due to the risk of ASM exposure rather than to an exposure to parental epilepsy. This conclusion is based on the fact that ASM-related teratogenesis varies by drug and that mothers with epilepsy not taking ASMs during pregnancy do not have an increased risk of MCMs in their children compared with the general population [<a href="#rid44">44</a>]. The effect of maternal epilepsy alone is difficult to study, however, as it can be argued that mothers with epilepsy not taking ASMs during pregnancy may have a milder condition. Paternal epilepsy does not seem to increase the risk of fetal malformations [<a href="#rid47">47</a>].</p><p>Data on major fetal malformations come from several international prospective and population-based registries that have been collecting data on ASM-exposed pregnancies for three decades  (<a class="graphic graphic_figure graphicRef142058" href="/z/d/graphic/142058.html" rel="external">figure 1</a>). These studies have differing methodologies, which accounts for some variability in findings. For the most part, however, they have yielded complementary results. Several of the registries do not have a control group of mothers without epilepsy. Thus, direct statistical comparison to the general population risk is not always possible. However, these registries do make it possible to compare MCM risk between different ASMs.</p><p>It is our practice to present absolute malformation risk where possible, as this is most meaningful to patients. As a reference, it is helpful to note that rates of malformations in the general population typically range from 2 to 3 percent.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Types of malformations</strong> – The most common major malformations associated with ASMs are neural tube, congenital heart, and urinary tract defects, as well as skeletal abnormalities and oral clefts [<a href="#rid42">42,48,49</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Different ASMs have different risks</strong> – Different ASMs carry substantially different levels of risk for major malformations. The risk associated with some ASMs is very close to that in the general population, while other ASMs (eg, <a class="drug drug_general" data-topicid="10035" href="/z/d/drug information/10035.html" rel="external">valproate</a>, <a class="drug drug_general" data-topicid="9763" href="/z/d/drug information/9763.html" rel="external">phenobarbital</a>, and <a class="drug drug_general" data-topicid="10006" href="/z/d/drug information/10006.html" rel="external">topiramate</a>) have a several-fold increased risk for major malformations [<a href="#rid50">50</a>].</p><p></p><p class="bulletIndent1">Across all pregnancy registries, <a class="drug drug_general" data-topicid="10035" href="/z/d/drug information/10035.html" rel="external">valproate</a> monotherapy is associated with the highest rates of major malformations compared with other ASMs [<a href="#rid45">45,46,50</a>]. A 2019 report from the International League Against Epilepsy (ILAE) concluded that valproate is associated with the highest risk of MCMs, while <a class="drug drug_general" data-topicid="9763" href="/z/d/drug information/9763.html" rel="external">phenobarbital</a> and <a class="drug drug_general" data-topicid="10006" href="/z/d/drug information/10006.html" rel="external">topiramate</a> are associated with an intermediate risk and <a class="drug drug_general" data-topicid="9545" href="/z/d/drug information/9545.html" rel="external">lamotrigine</a> and <a class="drug drug_general" data-topicid="9904" href="/z/d/drug information/9904.html" rel="external">levetiracetam</a> are associated with the lowest risk [<a href="#rid13">13</a>]. The consistency of findings across different pregnancy studies and in varied regions of the world strengthen the conclusion that some ASMs are associated with a higher risk for major malformations than others  (<a class="graphic graphic_figure graphicRef142058" href="/z/d/graphic/142058.html" rel="external">figure 1</a>). (See <a class="local">'Risks with specific ASMs'</a> below and  <a class="medical medical_review" href="/z/d/html/2224.html" rel="external">"Management of epilepsy during preconception, pregnancy, and the postpartum period", section on 'Changing antiseizure medications during pregnancy'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Timing and dose of ASM</strong> – In addition to the specific ASM exposure, the gestational timing of the exposure and the dose of the ASM used are also likely to be important. These have been best associated with <a class="drug drug_general" data-topicid="10035" href="/z/d/drug information/10035.html" rel="external">valproate</a> [<a href="#rid45">45,49,51-53</a>]. The International Registry of Antiepileptic Drugs and Pregnancy (EURAP) investigators analyzed the dose at the time of conception and reported a dose-dependent increase in the major malformation rates for monotherapy with valproate, <a class="drug drug_general" data-topicid="9763" href="/z/d/drug information/9763.html" rel="external">phenobarbital</a>, <a class="drug drug_general" data-topicid="9198" href="/z/d/drug information/9198.html" rel="external">carbamazepine</a>, and <a class="drug drug_general" data-topicid="9545" href="/z/d/drug information/9545.html" rel="external">lamotrigine</a>  (<a class="graphic graphic_figure graphicRef118222" href="/z/d/graphic/118222.html" rel="external">figure 2</a>) [<a href="#rid49">49,50</a>]. The ILAE working group concluded that the risk is dose dependent for valproate and is probably dose dependent for other ASMs including carbamazepine, phenobarbital and lamotrigine [<a href="#rid13">13</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Polytherapy</strong> – In general, ASM polytherapy is a risk factor for fetal major malformations, as identified in a number of prospective registry studies, with the rates of major malformations increasing to 6 to 8.6 percent [<a href="#rid44">44,46</a>]. However, the risk is probably more dependent upon the specific ASMs used as polytherapy, as well as the dose of those ASMs, rather than just the number of ASMs used [<a href="#rid13">13</a>]. Polytherapy with a regimen that includes <a class="drug drug_general" data-topicid="10035" href="/z/d/drug information/10035.html" rel="external">valproate</a> or <a class="drug drug_general" data-topicid="10006" href="/z/d/drug information/10006.html" rel="external">topiramate</a> is associated with a particularly high risk for MCMs [<a href="#rid54">54-56</a>]. By contrast, some polytherapy combinations, particularly <a class="drug drug_general" data-topicid="9545" href="/z/d/drug information/9545.html" rel="external">lamotrigine</a> and <a class="drug drug_general" data-topicid="9904" href="/z/d/drug information/9904.html" rel="external">levetiracetam</a>, are <strong>not</strong> associated with a substantially elevated risk for major malformations and are being used more commonly to avoid valproate use during pregnancy [<a href="#rid57">57</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>History of malformation</strong> – There are likely yet undefined genetic risk factors that predispose to ASM-associated teratogenesis. A family history of congenital malformations, including from the paternal side, and a low maternal level of education have been identified as additional risk factors for fetal major malformations, at least in some studies [<a href="#rid44">44,45,49,51,58-61</a>]. A previous ASM-exposed pregnancy resulting in MCMs is associated with an increased risk in subsequent pregnancies [<a href="#rid62">62,63</a>]. The risk appears to be particularly high for <a class="drug drug_general" data-topicid="10035" href="/z/d/drug information/10035.html" rel="external">valproate</a> and <a class="drug drug_general" data-topicid="10006" href="/z/d/drug information/10006.html" rel="external">topiramate</a> but may also be increased for other ASMs and in pregnancies exposed to polytherapy. In two different registry studies, women taking valproate who had a previous child with a major malformation had a recurrence risk of approximately 50 percent if they continued valproate during the subsequent pregnancy [<a href="#rid62">62,63</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Mechanism</strong> – The mechanism for ASM-induced teratogenicity has not been determined. One possibility is that some fetuses have low or deficient epoxide hydrolase activity that results in increased levels of teratogenic oxidative metabolites when they are exposed to ASMs [<a href="#rid54">54,64</a>]. Another mechanism involves oxidative damage to deoxyribonucleic acid (DNA) from free radical intermediates produced by prostaglandin H synthase bioactivation of ASMs [<a href="#rid65">65</a>]. Deficiency of <a class="drug drug_general" data-topicid="8475" href="/z/d/drug information/8475.html" rel="external">folic acid</a> has also been suggested to play a role in teratogenicity associated with ASMs, some of which are folic acid antagonists. (See  <a class="medical medical_review" href="/z/d/html/2224.html" rel="external">"Management of epilepsy during preconception, pregnancy, and the postpartum period", section on 'Folic acid supplementation'</a>.)</p><p></p><p class="headingAnchor" id="H3704802733"><span class="h2">Fetal growth restriction</span><span class="headingEndMark"> — </span>There is an increased risk of fetal growth restriction and delivery of an SGA infant with prenatal exposure to ASMs [<a href="#rid13">13,19,20</a>]. ASMs associated with increased risk in various studies include <a class="drug drug_general" data-topicid="10006" href="/z/d/drug information/10006.html" rel="external">topiramate</a>, <a class="drug drug_general" data-topicid="9862" href="/z/d/drug information/9862.html" rel="external">zonisamide</a>, <a class="drug drug_general" data-topicid="9198" href="/z/d/drug information/9198.html" rel="external">carbamazepine</a>, <a class="drug drug_general" data-topicid="10035" href="/z/d/drug information/10035.html" rel="external">valproate</a>, and <a class="drug drug_general" data-topicid="9763" href="/z/d/drug information/9763.html" rel="external">phenobarbital</a> [<a href="#rid13">13,20,66</a>]. The risk appears to be most pronounced with topiramate (see <a class="local">'Topiramate'</a> below). ASM polytherapy is also associated with an increased risk of fetal growth restriction [<a href="#rid13">13,67</a>]. One population-based study from Taiwan also found an increased risk of SGA infants in mothers with seizures during pregnancy (see <a class="local">'Effect of seizures on the fetus'</a> above) [<a href="#rid24">24</a>]. In this study, seizures were defined as those requiring emergency department or hospital treatment for seizures during pregnancy. However, the study could not control for specific ASM exposure, so the possibility that ASM effects contributed to SGA risk cannot be excluded.</p><p class="headingAnchor" id="H303817365"><span class="h2">Neurodevelopmental risks</span><span class="headingEndMark"> — </span>Accumulating evidence from observational studies suggests that ASM treatment during pregnancy can be associated with cognitive and behavioral effects that manifest later in the life of the offspring. Neurodevelopmental outcomes are well characterized for a few ASMs. Some but not all prospective studies have included children born to mothers without epilepsy, and some have accounted for parental intelligence quotient (IQ), which is an important determinant of child neurodevelopment. The degree of neurodevelopmental risk varies with the type of ASM and possibly the level of in utero<em> </em>exposure [<a href="#rid42">42,68-75</a>]. Where possible, ASM-specific information on exposure and neurodevelopment is included below for individual ASMs (see <a class="local">'Risks with specific ASMs'</a> below). Across all studies, <a class="drug drug_general" data-topicid="10035" href="/z/d/drug information/10035.html" rel="external">valproate</a> has consistently stood out as the ASM most clearly associated with poorer neurodevelopmental outcomes [<a href="#rid13">13</a>].</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Polytherapy</strong> – ASM polytherapy may present a higher risk of cognitive impairment than monotherapy [<a href="#rid8">8,72,76</a>], and verbal abilities may be particularly affected [<a href="#rid77">77,78</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Risk with malformations</strong> – Some studies find that the risk of cognitive impairments with ASM exposure is highest in children who also have one or more of the major malformations described above [<a href="#rid79">79-81</a>]. However, ASM-related neurocognitive effects can be seen in the absence of malformations.</p><p></p><p class="headingAnchor" id="H696587353"><span class="h2">Risks with specific ASMs</span><span class="headingEndMark"> — </span>The spectrum of fetal malformations and neurodevelopmental risks for different ASM monotherapies is depicted in the figure  (<a class="graphic graphic_figure graphicRef118230" href="/z/d/graphic/118230.html" rel="external">figure 3</a>). A summary of available data on the risks of exposure to specific ASMs is reviewed in the sections that follow.</p><p>Decisions about selecting or changing ASMs with pregnancy are discussed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/2224.html" rel="external">"Management of epilepsy during preconception, pregnancy, and the postpartum period"</a>.)</p><p class="headingAnchor" id="H6"><span class="h3">Valproate</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="10035" href="/z/d/drug information/10035.html" rel="external">Valproate</a> (VPA) should be avoided in females of childbearing age if possible.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Malformations</strong> – First-trimester maternal exposure to VPA increases the risk of major malformations, independent of any contribution of the epilepsy syndrome itself [<a href="#rid5">5,8,82</a>]. VPA exposure in utero is associated with the development of neural tube-like defects (eg, spina bifida, open lumbosacral myelocele) in 1 to 2 percent of fetuses, which represents a 10- to 20-fold increase over the general population [<a href="#rid50">50,83-85</a>]. Additional patterns of major malformations associated with first-trimester VPA exposure include oral clefts, cardiovascular and urogenital malformations, and multiple malformations [<a href="#rid49">49,50,79,86</a>].</p><p></p><p class="bulletIndent1">The North American Antiepileptic Drug Pregnancy Registry (NAAPR) followed 323 VPA-exposed pregnancies to completion [<a href="#rid87">87,88</a>]. The prevalence of MCMs in offspring of women who received VPA monotherapy was 9 percent, as compared with 3 percent in offspring of women receiving other ASMs and 1 percent in an unexposed control group. Thus, the relative risk of major malformations in VPA-exposed women was 9.0 (95% CI 3.4-23.3) [<a href="#rid88">88</a>]. Increased dose of VPA was also associated with increased risk (OR 3.7 for VPA ≤1500 mg/day versus OR 10.9 for VPA &gt;1500 mg/day) [<a href="#rid45">45</a>], a finding also seen in other studies [<a href="#rid49">49-51</a>].</p><p></p><p class="bulletIndent1">A case-control study using the European Surveillance of Congenital Anomalies database (registering a combined total of 98,075 MCMs) found that VPA was associated with an increased risk for several congenital malformations [<a href="#rid89">89</a>]. Compared with no ASMs, adjusted ORs for specific malformations were as follows: spina bifida (12.7), atrial septal defect (2.5), cleft palate (5.2), hypospadias (4.8), polydactyly (2.2), and craniosynostosis (6.8). ORs were similarly elevated for the comparison of VPA use with other ASM use.</p><p></p><p class="bulletIndent1">The effect of VPA on malformation risk is dose dependent, but a lowest safe dose has not been established [<a href="#rid52">52,53,90,91</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Neurodevelopment</strong> – Of all ASMs, VPA is the most strongly associated with adverse neurodevelopmental outcomes [<a href="#rid8">8,13,77,92-103</a>]. It has been specifically associated with a risk of lower IQ in exposed children [<a href="#rid77">77,95,96,98,100</a>] as well as an increased risk of autism spectrum disorder.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>IQ and language</strong> – The Neurodevelopmental Effects of Antiepileptic Drugs (NEAD) study, a prospective study of 309 children who had been exposed to ASMs in utero, found that at age three years, children exposed to VPA had IQ scores that were on average six to nine points lower than those exposed to <a class="drug drug_general" data-topicid="9545" href="/z/d/drug information/9545.html" rel="external">lamotrigine</a>, <a class="drug drug_general" data-topicid="9769" href="/z/d/drug information/9769.html" rel="external">phenytoin</a>, or <a class="drug drug_general" data-topicid="9198" href="/z/d/drug information/9198.html" rel="external">carbamazepine</a> [<a href="#rid95">95</a>]. These findings persisted at six years [<a href="#rid100">100</a>]. In addition, the relationship between IQ score and VPA exposure was dose related, and children's IQ scores were related to maternal IQ scores in all exposure groups except for VPA [<a href="#rid77">77</a>].</p><p></p><p class="bulletIndent2">A prospective blinded study of 182 children of mothers with epilepsy and 141 controls found significantly lower verbal IQ scores associated with exposure to VPA and ASM polytherapy but not to <a class="drug drug_general" data-topicid="9198" href="/z/d/drug information/9198.html" rel="external">carbamazepine</a> monotherapy [<a href="#rid96">96</a>]. In another registry-based study, 102 school-aged children exposed to VPA in utero had lower than mean average language test scores on blinded assessments [<a href="#rid97">97</a>]. Similarly, in a prospective study of 172 infants (mean age of 15 months), in utero exposure to VPA monotherapy was associated with lower mental and motor developmental quotients compared with carbamazepine monotherapy [<a href="#rid98">98</a>].</p><p></p><p class="bulletIndent2">VPA-associated language deficits persist to school age. An Indian study of 55 eleven-year-old children exposed to VPA in monotherapy or polytherapy in utero found that they had poorer standardized language scores than unexposed peers [<a href="#rid104">104</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Autism spectrum disorders</strong> – In utero exposure to VPA also appears to increase the risk of autism spectrum disorders [<a href="#rid13">13,99,105-108</a>]. In a population-based study of more than 650,000 children born in Denmark from 1996 through 2006 that included 6584 women with epilepsy, 2655 ASM-exposed pregnancies, and 508 VPA-exposed pregnancies, the risk of autism spectrum disorder was increased in children exposed to VPA in the overall study population (hazard ratio [HR] 2.9, 95% CI 1.7-4.9; absolute risk 4.4 percent), and there was a trend towards increased risk in VPA-exposed children born to mothers with epilepsy (HR 1.7, 95% CI 0.9-3.2; absolute risk 4.2 percent) [<a href="#rid108">108</a>]. For the more narrowly defined diagnostic code of childhood autism, the relative risk was increased fivefold (absolute risk 2.5 percent). Analyses were adjusted for parental age at conception, parental psychiatric history, gestational age, birth weight, sex of the child, congenital malformations, and parity. An increased risk of autism spectrum disorders was also seen in children exposed to VPA whose mothers had diagnoses other than epilepsy, but not in children of women who were previous users of VPA but stopped at least 30 days before conception; both factors increase confidence in the association. An increased risk was not seen in association with other ASMs, including <a class="drug drug_general" data-topicid="9198" href="/z/d/drug information/9198.html" rel="external">carbamazepine</a>, <a class="drug drug_general" data-topicid="9467" href="/z/d/drug information/9467.html" rel="external">oxcarbazepine</a>, <a class="drug drug_general" data-topicid="9545" href="/z/d/drug information/9545.html" rel="external">lamotrigine</a>, and <a class="drug drug_general" data-topicid="9284" href="/z/d/drug information/9284.html" rel="external">clonazepam</a>, although the number of events in these subgroups was low.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Neonatal coagulopathy</strong> – Rare cases of neonatal coagulopathy due to VPA-induced hypofibrinogenemia have been reported [<a href="#rid109">109,110</a>].</p><p></p><p class="headingAnchor" id="H3641744441"><span class="h3">Carbamazepine</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Malformations</strong> – The rates of major malformations associated with <a class="drug drug_general" data-topicid="9198" href="/z/d/drug information/9198.html" rel="external">carbamazepine</a> monotherapy range from 2.6 to 5.9 percent in the prospective observational epilepsy and pregnancy registries [<a href="#rid46">46,50,66,88,111-114</a>]. Carbamazepine does have a specific association with neural tube defects [<a href="#rid8">8,48,85,115-117</a>]. In the European Registration of Congenital Anomalies and Twins (EUROCAT) database, exposure to carbamazepine monotherapy was associated with an increased risk of neural tube defects compared with controls on no ASM (OR 2.6; 95% CI 1.2-5.3) [<a href="#rid115">115</a>]. However, the EUROCAT study also showed that the risk of neural tube defects with carbamazepine exposure was lower than the risk with <a class="drug drug_general" data-topicid="10035" href="/z/d/drug information/10035.html" rel="external">valproate</a> exposure (OR 0.2; 95% CI 0.1-0.6). Based on aggregate data from several ASM pregnancy registries, the rate of specific malformations with carbamazepine monotherapy was 0.3 percent for neural tube defects, 0.8 percent for cardiac malformations, 0.4 percent for hypospadias, and 0.36 percent for oral clefts, respectively [<a href="#rid86">86</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Neurodevelopment</strong> – Studies on the neurodevelopmental effects of <a class="drug drug_general" data-topicid="9198" href="/z/d/drug information/9198.html" rel="external">carbamazepine</a> exposure have presented mixed results. However, much of this variability is felt to be due to differences in methodology [<a href="#rid101">101,118</a>]. The majority of studies, including well-designed prospective studies, support normal cognitive performance in children exposed to carbamazepine in utero [<a href="#rid8">8,73,76,77,100-102,119-121</a>]. In the NEAD study, the IQ of six-year-old children exposed to carbamazepine monotherapy in utero did not differ from that of children exposed to <a class="drug drug_general" data-topicid="9769" href="/z/d/drug information/9769.html" rel="external">phenytoin</a> or <a class="drug drug_general" data-topicid="9545" href="/z/d/drug information/9545.html" rel="external">lamotrigine</a> [<a href="#rid100">100</a>]. However, compared with valproate-exposed children, carbamazepine-exposed children had a higher mean full-scale IQ score. In an overlapping prospective study from the United Kingdom, the adjusted mean IQ of children exposed to carbamazepine monotherapy did not differ from that of unexposed control children [<a href="#rid102">102</a>]. However, there was an increased risk of having an IQ &lt;85 in the carbamazepine group.</p><p></p><p class="bulletIndent1">There are limited data on the risk of behavioral abnormalities in children exposed to <a class="drug drug_general" data-topicid="9198" href="/z/d/drug information/9198.html" rel="external">carbamazepine</a>. In a population-based study from Denmark, there was no increased risk of formally diagnosed autism spectrum disorder in school-aged and teenaged children exposed to carbamazepine in utero [<a href="#rid108">108</a>]. Similarly, a prospective study from the United Kingdom did not identify any increased risk of a formally diagnosed neurodevelopmental disorder [<a href="#rid107">107</a>].</p><p></p><p class="headingAnchor" id="H1550105935"><span class="h3">Gabapentin</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Malformations</strong> – Several small case-control studies as well as larger registry-based studies that include a limited number of gabapentin-exposed pregnancies have found no association between <a class="drug drug_general" data-topicid="8483" href="/z/d/drug information/8483.html" rel="external">gabapentin</a> and MCMs [<a href="#rid88">88,122-124</a>]. A prospective cohort study reported on 223 gabapentin-exposed pregnancies compared with 223 unexposed [<a href="#rid123">123</a>]. Rates of major malformations were similar. However, the gabapentin-exposed group had higher rates of preterm births and low birth weight &lt;2500 grams. The admission rate to either the neonatal intensive care unit or special care nursery for observation with continued gabapentin use was 38 percent, versus 3 percent in the comparison group. Only one-third of women were prescribed gabapentin for epilepsy, and most pregnancies involved other neuropsychiatric medications.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Neurodevelopment</strong> – Data on neurodevelopmental outcomes with in utero <a class="drug drug_general" data-topicid="8483" href="/z/d/drug information/8483.html" rel="external">gabapentin</a> exposure are too limited to draw firm conclusions [<a href="#rid119">119</a>].</p><p></p><p class="headingAnchor" id="H2512257553"><span class="h3">Lamotrigine</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Congenital malformations</strong> – Prospective pregnancy registries have reported a 2 to 4.9 percent incidence of major malformations after first-trimester exposure to <a class="drug drug_general" data-topicid="9545" href="/z/d/drug information/9545.html" rel="external">lamotrigine</a> monotherapy [<a href="#rid88">88,125,126</a>]. However, the data regarding dose-related risk of lamotrigine have been conflicting. While the International Lamotrigine Pregnancy Registry found no effect of lamotrigine dose, up to 400 mg/day, on the incidence of major malformations [<a href="#rid126">126,127</a>], the United Kingdom Epilepsy and Pregnancy Registry did observe a dose relationship [<a href="#rid46">46</a>]. In the EURAP registry, the incidence of fetal malformations with lamotrigine at any dose was 3 percent, but it was significantly higher for patients taking &gt;325 mg per day at conception than for patients taking lower doses (4.3 versus 2.5 percent) [<a href="#rid50">50</a>]. They did not have data on doses during the remainder of the first trimester or lamotrigine blood concentrations.</p><p></p><p class="bulletIndent1">A report from the NAAPR noted a higher-than-expected prevalence of cleft palate and/or cleft lip in infants exposed to <a class="drug drug_general" data-topicid="9545" href="/z/d/drug information/9545.html" rel="external">lamotrigine</a> in the first trimester (8.9 per 1000 compared with the expected 0.7 to 2.5 per 1000) [<a href="#rid128">128</a>]. However, population-based case-control studies derived from a European congenital anomaly register found that lamotrigine monotherapy did not specifically increase the risk of isolated orofacial clefts relative to other malformations [<a href="#rid129">129,130</a>]. These studies were not designed to study whether lamotrigine was associated with an overall risk of malformations and therefore could not determine an association.</p><p></p><p class="bulletIndent1">Data released from the manufacturer's pregnancy registry in January 2008 reported that the risk of major malformations after exposure to <a class="drug drug_general" data-topicid="9545" href="/z/d/drug information/9545.html" rel="external">lamotrigine</a> used in polytherapy with other ASMs, not including <a class="drug drug_general" data-topicid="10035" href="/z/d/drug information/10035.html" rel="external">valproate</a>, was similar to that of lamotrigine monotherapy but was increased in those exposed to lamotrigine and valproate (16 of 143 pregnancies, 11 percent) [<a href="#rid125">125</a>]. These findings were similar in the final report of the International Lamotrigine Pregnancy Registry [<a href="#rid126">126</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Neurodevelopment</strong> – In multiple independent studies, developmental and cognitive abilities of lamotrigine-exposed children have been consistently measured as not different from unexposed control groups and improved compared with valproate-exposed children [<a href="#rid13">13,119,131,132</a>]. While some studies have suggested an increase in parent-reported "autistic traits" in lamotrigine-exposed children, this was not associated with increases in neurodevelopmental referrals [<a href="#rid119">119</a>]. Furthermore, studies examining the rates of formally diagnosed attention deficit/hyperactivity disorder (ADHD) or autism spectrum disorder have not found an increased risk in lamotrigine-exposed children compared with controls [<a href="#rid119">119</a>].</p><p></p><p class="headingAnchor" id="H2791923186"><span class="h3">Levetiracetam</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Malformations</strong> – Across prospective pregnancy registries, rates of major malformations with <a class="drug drug_general" data-topicid="9904" href="/z/d/drug information/9904.html" rel="external">levetiracetam</a> monotherapy exposure have ranged from 0.7 to 4.7 percent [<a href="#rid114">114</a>]. A Cochrane review reported an aggregate malformation rate of 1.77 percent for levetiracetam in 817 published pregnancies [<a href="#rid133">133</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Neurodevelopment</strong> – Data are limited and inconsistent regarding intrauterine exposure to <a class="drug drug_general" data-topicid="9904" href="/z/d/drug information/9904.html" rel="external">levetiracetam</a> monotherapy and early developmental outcomes. Most studies found no harmful effects [<a href="#rid92">92,119,132,134,135</a>], and some suggested that levetiracetam monotherapy exposure in utero was not associated with later cognitive deficits up to age nine years [<a href="#rid92">92,135</a>]. However, in a population-based cohort study of over 38,000 children of mothers with epilepsy from Scandinavian countries (SCAN-AED), prenatal exposure to levetiracetam was associated with increased rates of anxiety (adjusted hazard ratio [aHR] 2.17; 95% CI 1.26-3.72) and attention deficit hyperactivity disorder (aHR 1.78; 95% CI 1.03-3.07) [<a href="#rid136">136</a>].</p><p></p><p class="bulletIndent1">The Maternal Outcomes and Neurodevelopmental Effects of Antiepileptic Drugs (MONEAD) study did show that higher third-trimester blood levels of <a class="drug drug_general" data-topicid="9904" href="/z/d/drug information/9904.html" rel="external">levetiracetam</a> were associated with poorer developmental scores in the language domain at ages two years and three years [<a href="#rid41">41,131</a>]. The significance of this finding will need to be clarified as this cohort of children grows older.</p><p></p><p class="headingAnchor" id="H753406704"><span class="h3">Oxcarbazepine</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Malformations</strong> – <a class="drug drug_general" data-topicid="9467" href="/z/d/drug information/9467.html" rel="external">Oxcarbazepine</a> cohorts in the prospective pregnancy registries have been small, and the incidence of major malformation rates ranges from 2.2 to 7 percent [<a href="#rid114">114</a>]. In a registry-based study in Denmark, MCMs were detected in 11 of 393 infants (2.8 percent) exposed to oxcarbazepine, a rate that was not significantly higher than in nonexposed infants [<a href="#rid122">122</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Neurodevelopment</strong> – Data on neurocognitive outcomes related to <a class="drug drug_general" data-topicid="9467" href="/z/d/drug information/9467.html" rel="external">oxcarbazepine</a> exposure are too limited to draw meaningful conclusions [<a href="#rid119">119</a>]. In the SCAN-AED cohort, which included 1460 oxcarbazepine-exposed children, prenatal oxcarbazepine exposure was not associated with any clinically diagnosed psychiatric disorders, including intellectual disability and autism spectrum disorders [<a href="#rid136">136</a>].</p><p></p><p class="headingAnchor" id="H8"><span class="h3">Phenobarbital</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Malformations</strong> – Cardiac, orofacial, and urogenital malformations occur with increased frequency with in utero <a class="drug drug_general" data-topicid="9763" href="/z/d/drug information/9763.html" rel="external">phenobarbital</a> exposure [<a href="#rid8">8,48,86,137-140</a>]. A study from the NAAPR reported a 5.5 percent incidence of major malformations among 199 pregnancies associated with phenobarbital use, a rate that was somewhat higher than for unexposed pregnancies and for those exposed to <a class="drug drug_general" data-topicid="9545" href="/z/d/drug information/9545.html" rel="external">lamotrigine</a> [<a href="#rid88">88</a>]. Similar rates have been seen in the Kerala (5.8 percent) and EURAP (6.5 percent) registries [<a href="#rid50">50,113</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Neurodevelopment</strong> – Data on neurocognitive outcomes of children exposed to maternal epilepsy and <a class="drug drug_general" data-topicid="9763" href="/z/d/drug information/9763.html" rel="external">phenobarbital</a> are limited [<a href="#rid118">118,141</a>]. One study of 61 school children (average age 11 years) in India demonstrated that children exposed to phenobarbital monotherapy or polytherapy in utero had poorer standardized language scores compared with their unexposed peers [<a href="#rid104">104</a>]. Another study from the United States of 34 children (average age nine years) who were exposed to phenobarbital in utero found that they had lower full-scale IQ (adjusted difference 8.51; 95% CI 1.88-15.13) and verbal IQ (adjusted difference 9.2; 95% CI 2.76-15.65) scores compared with control children [<a href="#rid141">141</a>].</p><p></p><p class="headingAnchor" id="H2239052363"><span class="h3">Phenytoin</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Malformations – </strong>The overall rates of MCMs among pregnancies exposed to <a class="drug drug_general" data-topicid="9769" href="/z/d/drug information/9769.html" rel="external">phenytoin</a> monotherapy in the EURAP and NAAPR registries were 2.9 and 6.4 percent, respectively  (<a class="graphic graphic_figure graphicRef142058" href="/z/d/graphic/142058.html" rel="external">figure 1</a>) [<a href="#rid50">50,88</a>]. Orofacial clefts, cardiac malformations, and genitourinary defects are the major malformations described with phenytoin [<a href="#rid8">8,48,52,86,137,138,142</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Neurodevelopment</strong> – Historical studies on the impact of <a class="drug drug_general" data-topicid="9769" href="/z/d/drug information/9769.html" rel="external">phenytoin</a> exposure on neurocognitive development have been small, with methodologic limitations [<a href="#rid101">101,118</a>]. In the NEAD study, six-year-old children exposed to phenytoin monotherapy in utero had a mean IQ that was superior to the IQ of children exposed to <a class="drug drug_general" data-topicid="10035" href="/z/d/drug information/10035.html" rel="external">valproate</a> and similar to the mean IQ of children exposed to <a class="drug drug_general" data-topicid="9198" href="/z/d/drug information/9198.html" rel="external">carbamazepine</a> or <a class="drug drug_general" data-topicid="9545" href="/z/d/drug information/9545.html" rel="external">lamotrigine</a> [<a href="#rid100">100</a>].</p><p></p><p class="headingAnchor" id="H553116762"><span class="h3">Pregabalin</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Malformations</strong> – In a multicenter observational study, first-trimester exposure to <a class="drug drug_general" data-topicid="9473" href="/z/d/drug information/9473.html" rel="external">pregabalin</a> (mostly for indications other than seizure disorder) was associated with an increased rate of MCMs compared with no exposure (6 versus 2 percent) [<a href="#rid143">143</a>]. The small number of exposed pregnancies (n = 164), high rates of polytherapy and tobacco use among women taking pregabalin, and differences in medical comorbidities between exposed and unexposed women limit confidence in these findings, and more studies are needed [<a href="#rid144">144</a>]. A subsequent population-based study nested in the United States Medicaid Analytic eXtract did not find a difference in malformation rates in pregabalin exposed pregnancies compared with the general population (aRR 1.03, 95% CI 0.56-1.90) [<a href="#rid145">145</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Neurodevelopment</strong> – There are no meaningful data on neurocognitive outcomes in infants and children exposed to <a class="drug drug_general" data-topicid="9473" href="/z/d/drug information/9473.html" rel="external">pregabalin</a> in utero.</p><p></p><p class="headingAnchor" id="H2562210836"><span class="h3">Topiramate</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Malformations</strong> – The overall risk of malformations with <a class="drug drug_general" data-topicid="10006" href="/z/d/drug information/10006.html" rel="external">topiramate</a> monotherapy exposure ranges from 3.9 to 4.2 percent in larger cohorts  (<a class="graphic graphic_figure graphicRef142058" href="/z/d/graphic/142058.html" rel="external">figure 1</a>) [<a href="#rid114">114</a>]. The risk of fetal malformations is increased further in association with polytherapy regimens that include topiramate. In an Australian registry cohort study, for example, the fetal malformation rate was more than two times higher in polytherapy pregnancies that included topiramate compared with those that did not (14.9 versus 6.6 percent) [<a href="#rid54">54</a>]. Additionally, a significant and reproducible risk of oral clefts with topiramate exposure has raised concerns that it is a significant teratogen.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Oral clefts</strong> – Across multiple studies, the estimated absolute risk of oral clefts in a topiramate-exposed pregnancy has ranged from approximately 4 to 29 per 1000 births, compared with an expected unexposed risk in the background population of 1 to 2 per 1000 births [<a href="#rid88">88,122,146-149</a>]. At the lower end of this range, a population-based study nested in the United States Medicaid Analytic eXtract found that the risk of oral clefts at birth was 4.1 per 1000 in the infants born to women exposed to <a class="drug drug_general" data-topicid="10006" href="/z/d/drug information/10006.html" rel="external">topiramate</a> compared with 1.1 per 1000 in the unexposed group (RR 2.90, 95% CI 1.56-5.40) [<a href="#rid146">146</a>]. The increased risk of oral clefts associated with use of topiramate early in pregnancy was more pronounced in women with epilepsy, who used higher doses, and is likely another example of a dose-dependent risk for a major malformation.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Growth</strong> – <a class="drug drug_general" data-topicid="10006" href="/z/d/drug information/10006.html" rel="external">Topiramate</a> use in pregnancy is associated with an increased risk for fetal growth restriction and low birth weight [<a href="#rid13">13</a>]. In studies from the NAAPR, the prevalence of SGA was 18 percent in topiramate-exposed neonates compared with 7 and 5 percent in lamotrigine-exposed neonates and unexposed controls, respectively [<a href="#rid19">19,66</a>]. The risk of SGA was significantly elevated for topiramate (RR 3.5, 95% CI 2.1-5.7) compared with controls after adjusting for multiple factors, including maternal age, parity, smoking status, education, and periconceptional <a class="drug drug_general" data-topicid="8475" href="/z/d/drug information/8475.html" rel="external">folic acid</a> intake.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Neurodevelopment</strong> – Limited data suggest that in utero <a class="drug drug_general" data-topicid="10006" href="/z/d/drug information/10006.html" rel="external">topiramate</a> exposure is associated with an increased risk of neurodevelopmental problems, leading the Pharmacovigilance Risk Assessment Committee (PRAC) of the European Medicines Agency to recommend avoidance of topiramate exposure in pregnancy unless there is no other suitable treatment available [<a href="#rid150">150</a>].</p><p></p><p class="bulletIndent1">In a population-based study from the SCAN-AED cohort of over 38,000 children of mothers with epilepsy, prenatal exposure to <a class="drug drug_general" data-topicid="10006" href="/z/d/drug information/10006.html" rel="external">topiramate</a> (n = 290) was associated with an increased risk of attention deficit hyperactivity disorder (aHR 2.38; 95% CI 1.40-4.06) and trends toward increased risk of autism spectrum disorder (aHR 1.93; 95% CI 0.95-3.94) and intellectual disability (aHR 2.23; 95% CI 0.90-5.50) [<a href="#rid136">136</a>].</p><p></p><p class="headingAnchor" id="H1306968501"><span class="h3">Zonisamide</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Malformations</strong> – <a class="drug drug_general" data-topicid="9862" href="/z/d/drug information/9862.html" rel="external">Zonisamide</a> monotherapy cohorts have been small, with malformation rates ranging from 0 to 13 percent [<a href="#rid11">11,50,66,151</a>]. When pooled, out of the 138 prospective pregnancies published, a major malformation was present in 2.9 percent.</p><p></p><p class="bulletIndent1"><a class="drug drug_general" data-topicid="9862" href="/z/d/drug information/9862.html" rel="external">Zonisamide</a> has also been associated with fetal growth restriction. In reports from the NAAPR, the prevalence of SGA was 12 percent in zonisamide-exposed neonates compared with 7 and 5 percent in lamotrigine-exposed neonates and unexposed controls, respectively (RR 2.2, 95% CI 1.1-4.4) [<a href="#rid19">19,66</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Neurodevelopment</strong> – There is no meaningful evidence on neurocognitive outcomes in infants and children exposed to <a class="drug drug_general" data-topicid="9862" href="/z/d/drug information/9862.html" rel="external">zonisamide</a> in utero.</p><p></p><p class="headingAnchor" id="H14821226"><span class="h3">Other ASMs</span><span class="headingEndMark"> — </span>There is limited human information on the fetal risks of other ASMs (eg, <a class="drug drug_general" data-topicid="126259" href="/z/d/drug information/126259.html" rel="external">cenobamate</a>, <a class="drug drug_general" data-topicid="8719" href="/z/d/drug information/8719.html" rel="external">clobazam</a>, <a class="drug drug_general" data-topicid="91586" href="/z/d/drug information/91586.html" rel="external">eslicarbazepine</a>, <a class="drug drug_general" data-topicid="8934" href="/z/d/drug information/8934.html" rel="external">felbamate</a>, <a class="drug drug_general" data-topicid="10268" href="/z/d/drug information/10268.html" rel="external">lacosamide</a>, <a class="drug drug_general" data-topicid="87037" href="/z/d/drug information/87037.html" rel="external">perampanel</a>, <a class="drug drug_general" data-topicid="10144" href="/z/d/drug information/10144.html" rel="external">tiagabine</a>). Patients should be counseled that the risks of in utero exposure to these medications are largely unknown.</p><p class="headingAnchor" id="H15"><span class="h1">INHERITANCE OF EPILEPSY</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Risk</strong> – The prevalence of epilepsy is approximately 0.5 to 1 percent of the general population. The likelihood of developing epilepsy is modestly higher in children of a parent with epilepsy, and the degree of risk varies with the type of epilepsy syndrome [<a href="#rid152">152-156</a>].</p><p></p><p class="bulletIndent1">The best estimates of familial risk come from a population-based study that included 660 individuals with epilepsy and nearly 2500 first-degree relatives living in a single county in the northern United States [<a href="#rid156">156</a>]. The cumulative incidence of any form of epilepsy by age 40 years was 4.5 percent among individuals with a first-degree relative with epilepsy, which was threefold higher than the incidence in the general population. The risk was highest for relatives of individuals with generalized epilepsy (standardized incidence ratio [SIR] 8.3) and lowest for relatives of those with focal epilepsy (SIR 2.6). If a parent had epilepsy, the risk to offspring was 3.9 percent. The risk to a child was greater if the mother had epilepsy; children born to a mother with generalized epilepsy had the highest risk of developing epilepsy (8.3 percent). These epidemiologic data are useful for most prospective parents with epilepsy, as the risk of epilepsy in their children is often much lower than they assume. However, it is best applied to patients without a known genetic syndrome.</p><p></p><p class="bulletIndent1">The ability to stratify risk based on specific genetic findings is clinically available for some patients with epilepsy, and the use of genetic testing in adults with epilepsy is growing.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Genetic counseling</strong> – Genetic counseling and testing for epilepsy are not typically included in standard preconception genetic testing and carrier screening. During preconception counseling for any prospective parent with epilepsy, regardless of sex, it is important to consider the etiology of their epilepsy and whether they could have an epilepsy syndrome with implications for a child.</p><p></p><p class="bulletIndent1">A referral for genetic counseling should be considered for patients with first-degree relatives with epilepsy. However, many patients with heritable genetic syndromes may not have affected relatives. Thus, it is also important to recognize the clinical hallmarks of specific epilepsy syndromes that should prompt genetic counseling even in the absence of family history  (<a class="graphic graphic_table graphicRef142076" href="/z/d/graphic/142076.html" rel="external">table 1</a>). Some examples of specific syndromes include:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Autosomal dominant lateral temporal epilepsy (ADLTE) (see  <a class="medical medical_review" href="/z/d/html/2231.html" rel="external">"Focal epilepsy: Causes and clinical features", section on 'Genetic focal epilepsy syndromes'</a>)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Familial focal epilepsy with variable foci (FFEVF) (see  <a class="medical medical_review" href="/z/d/html/2231.html" rel="external">"Focal epilepsy: Causes and clinical features", section on 'Genetic focal epilepsy syndromes'</a>)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>FLNA-associated periventricular nodular heterotopia [<a href="#rid157">157</a>]</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Genetic epilepsy with febrile seizures plus (GEFS+)/SCN1A spectrum disorder (see  <a class="medical medical_review" href="/z/d/html/6183.html" rel="external">"Clinical features and evaluation of febrile seizures", section on 'Genetic epilepsies with febrile seizures'</a> and  <a class="medical medical_review" href="/z/d/html/108278.html" rel="external">"Dravet syndrome: Genetics, clinical features, and diagnosis"</a>)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Mitochondrial disorders (see  <a class="medical medical_review" href="/z/d/html/5151.html" rel="external">"Mitochondrial myopathies: Clinical features and diagnosis"</a>)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Tuberous sclerosis complex (see  <a class="medical medical_review" href="/z/d/html/6175.html" rel="external">"Tuberous sclerosis complex: Clinical features"</a>)</p><p></p><p class="bulletIndent1">Finally, patients with epilepsy in the setting of intellectual disability or autism spectrum disorder should also be offered genetic counseling, even in the absence of family history.</p><p></p><p class="headingAnchor" id="H179867437"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/113971.html" rel="external">"Society guideline links: Seizures and epilepsy in adults"</a>.)</p><p class="headingAnchor" id="H10160532"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)</p><p class="bulletIndent1"><span class="glyph">●</span>Basics topic (see  <a class="medical medical_basics" href="/z/d/html/16570.html" rel="external">"Patient education: Epilepsy and pregnancy (The Basics)"</a>)</p><p></p><p class="headingAnchor" id="H17"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Morbidity and mortality</strong> – While most pregnancies will be uncomplicated, there can be a higher risk of certain complications. Morbidity and mortality are increased during pregnancy among women with epilepsy compared with the general population across a range of maternal and neonatal outcomes, including pre-eclampsia, preterm labor, bleeding, placental abruption, poor fetal growth, prematurity, fetal death, and maternal mortality. The magnitude of the increase in risk appears to be relatively small for most complications (ie, between 1 and 1.5 times expected rates), with the exception of maternal mortality, which may be as much as five-fold higher among women with epilepsy during the delivery hospitalization. Despite the large increase in relative risk of maternal death, the increase in absolute risk is less than 0.1 percent. (See <a class="local">'Morbidity and mortality'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Seizures and fetal harm</strong> – Seizures, particularly convulsive seizures, are believed to be harmful to the fetus. Fetal bradycardia has been documented during nonconvulsive maternal seizures with impaired awareness (focal impaired awareness seizures, previously known as complex partial seizures). (See <a class="local">'Effect of seizures on the fetus'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pregnancy and its effect on epilepsy</strong> – Most pregnant patients with epilepsy will have no alteration of their seizure pattern during pregnancy, especially if nonadherence and sleep deprivation are minimized and the individual antiseizure medication (ASM) target concentrations are maintained with therapeutic drug monitoring. The main risk factors for increased seizures during pregnancy include baseline seizure frequency before pregnancy and focal epilepsy syndromes. Others include ASM type, polytherapy, and medication adherence. Altered pharmacokinetics of ASMs during pregnancy can contribute to increased seizure frequency if therapeutic drug monitoring is not used to maintain the target blood concentration. (See <a class="local">'Effect of pregnancy on seizures'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Risk of malformations</strong> – Major congenital malformations are more common in fetuses exposed to ASMs in utero compared with offspring of untreated women with epilepsy and women without epilepsy. The overall risk varies substantially by the ASM prescribed  (<a class="graphic graphic_figure graphicRef118230" href="/z/d/graphic/118230.html" rel="external">figure 3</a>). Across all pregnancy registries, <a class="drug drug_general" data-topicid="10035" href="/z/d/drug information/10035.html" rel="external">valproate</a> monotherapy is associated with the highest rates of major malformations. The dose of the ASM at the time of conception has also been associated with malformation risk for several ASMs. Some ASM polytherapy regimens, particularly those that include valproate or <a class="drug drug_general" data-topicid="10006" href="/z/d/drug information/10006.html" rel="external">topiramate</a>, also increase the risk. (See <a class="local">'Major congenital malformations and their risk factors'</a> above and <a class="local">'Risks with specific ASMs'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Neurodevelopmental risks</strong> – In utero exposure to some ASMs is associated with impaired cognitive and behavioral development  (<a class="graphic graphic_figure graphicRef118230" href="/z/d/graphic/118230.html" rel="external">figure 3</a>). The evidence for this association is strongest with <a class="drug drug_general" data-topicid="10035" href="/z/d/drug information/10035.html" rel="external">valproate</a>, which has been associated with impaired cognitive development as well as an increased risk of autism spectrum disorders. There is increasing concern about the impact of <a class="drug drug_general" data-topicid="10006" href="/z/d/drug information/10006.html" rel="external">topiramate</a> exposure on neurodevelopmental risk, though additional research is needed. (See <a class="local">'Neurodevelopmental risks'</a> above and <a class="local">'Risks with specific ASMs'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Ideally, avoid </strong><a class="drug drug_general" data-topicid="10035" href="/z/d/drug information/10035.html" rel="external">valproate</a> – Valproate should be avoided in women of childbearing age if possible. If valproate is essential for seizure control, lowering the dose of valproate should be tried, ideally well in advance of pregnancy. (See <a class="local">'Valproate'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Risk of inheriting epilepsy</strong> – For most prospective parents with epilepsy, the risk of passing epilepsy on to their child is 3.9 percent based on epidemiologic data. However, it is important to consider the etiology of epilepsy in preconception genetic counseling and to refer appropriate or interested patients for epilepsy-specific genetic counseling. (See <a class="local">'Inheritance of epilepsy'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Mitigating risks</strong> – Risks associated with pregnancy and epilepsy can be minimized by preconception planning and careful management during pregnancy, as reviewed separately. (See  <a class="medical medical_review" href="/z/d/html/2224.html" rel="external">"Management of epilepsy during preconception, pregnancy, and the postpartum period"</a>.)</p><p></p><p class="headingAnchor" id="H739986711"><span class="h1">ACKNOWLEDGMENT</span><span class="headingEndMark"> — </span>The UpToDate editorial staff acknowledges Page B Pennell, MD, who contributed to earlier versions of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Viale L, Allotey J, Cheong-See F, et al. Epilepsy in pregnancy and reproductive outcomes: a systematic review and meta-analysis. Lancet 2015; 386:1845.</a></li><li><a class="nounderline abstract_t">Razaz N, Tomson T, Wikström AK, Cnattingius S. Association Between Pregnancy and Perinatal Outcomes Among Women With Epilepsy. JAMA Neurol 2017; 74:983.</a></li><li><a class="nounderline abstract_t">MacDonald SC, Bateman BT, McElrath TF, Hernández-Díaz S. Mortality and Morbidity During Delivery Hospitalization Among Pregnant Women With Epilepsy in the United States. JAMA Neurol 2015; 72:981.</a></li><li><a class="nounderline abstract_t">Richmond JR, Krishnamoorthy P, Andermann E, Benjamin A. Epilepsy and pregnancy: an obstetric perspective. Am J Obstet Gynecol 2004; 190:371.</a></li><li><a class="nounderline abstract_t">Veiby G, Daltveit AK, Engelsen BA, Gilhus NE. Pregnancy, delivery, and outcome for the child in maternal epilepsy. Epilepsia 2009; 50:2130.</a></li><li><a class="nounderline abstract_t">Borthen I, Eide MG, Daltveit AK, Gilhus NE. Obstetric outcome in women with epilepsy: a hospital-based, retrospective study. BJOG 2011; 118:956.</a></li><li><a class="nounderline abstract_t">Harden CL, Hopp J, Ting TY, et al. Practice parameter update: management issues for women with epilepsy--focus on pregnancy (an evidence-based review): obstetrical complications and change in seizure frequency: report of the Quality Standards Subcommittee and Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and American Epilepsy Society. Neurology 2009; 73:126.</a></li><li><a class="nounderline abstract_t">Harden CL, Meador KJ, Pennell PB, et al. Practice parameter update: management issues for women with epilepsy--focus on pregnancy (an evidence-based review): teratogenesis and perinatal outcomes: report of the Quality Standards Subcommittee and Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and American Epilepsy Society. Neurology 2009; 73:133.</a></li><li><a class="nounderline abstract_t">Borthen I, Eide MG, Veiby G, et al. Complications during pregnancy in women with epilepsy: population-based cohort study. BJOG 2009; 116:1736.</a></li><li><a class="nounderline abstract_t">Soontornpun A, Choovanichvong T, Tongsong T. Pregnancy outcomes among women with epilepsy: A retrospective cohort study. Epilepsy Behav 2018; 82:52.</a></li><li><a class="nounderline abstract_t">Meador KJ, Pennell PB, May RC, et al. Fetal loss and malformations in the MONEAD study of pregnant women with epilepsy. Neurology 2020; 94:e1502.</a></li><li><a class="nounderline abstract_t">Mazzone PP, Hogg KM, Weir CJ, et al. Comparison of Perinatal Outcomes for Women With and Without Epilepsy: A Systematic Review and Meta-analysis. JAMA Neurol 2023; 80:484.</a></li><li><a class="nounderline abstract_t">Tomson T, Battino D, Bromley R, et al. Management of epilepsy in pregnancy: a report from the International League Against Epilepsy Task Force on Women and Pregnancy. Epileptic Disord 2019; 21:497.</a></li><li><a class="nounderline abstract_t">Kapoor D, Wallace S. Trends in maternal deaths from epilepsy in the United Kingdom: a 30-year retrospective review. Obstet Med 2014; 7:160.</a></li><li><a class="nounderline abstract_t">Edey S, Moran N, Nashef L. SUDEP and epilepsy-related mortality in pregnancy. Epilepsia 2014; 55:e72.</a></li><li><a class="nounderline abstract_t">Pennell PB, French JA, Harden CL, et al. Fertility and Birth Outcomes in Women With Epilepsy Seeking Pregnancy. JAMA Neurol 2018; 75:962.</a></li><li><a class="nounderline abstract_t">EURAP Study Group. Seizure control and treatment in pregnancy: observations from the EURAP epilepsy pregnancy registry. Neurology 2006; 66:354.</a></li><li><a class="nounderline abstract_t">Bech BH, Kjaersgaard MI, Pedersen HS, et al. Use of antiepileptic drugs during pregnancy and risk of spontaneous abortion and stillbirth: population based cohort study. BMJ 2014; 349:g5159.</a></li><li><a class="nounderline abstract_t">Hernández-Díaz S, McElrath TF, Pennell PB, et al. Fetal growth and premature delivery in pregnant women on antiepileptic drugs. Ann Neurol 2017; 82:457.</a></li><li><a class="nounderline abstract_t">Kilic D, Pedersen H, Kjaersgaard MI, et al. Birth outcomes after prenatal exposure to antiepileptic drugs--a population-based study. Epilepsia 2014; 55:1714.</a></li><li><a class="nounderline abstract_t">McElrath TF, Druzin M, Van Marter LJ, et al. The Obstetrical Care and Delivery Experience of Women with Epilepsy in the MONEAD Study. Am J Perinatol 2022.</a></li><li><a class="nounderline abstract_t">Teramo K, Hiilesmaa V, Bardy A, Saarikoski S. Fetal heart rate during a maternal grand mal epileptic seizure. J Perinat Med 1979; 7:3.</a></li><li><a class="nounderline abstract_t">Nei M, Daly S, Liporace J. A maternal complex partial seizure in labor can affect fetal heart rate. Neurology 1998; 51:904.</a></li><li><a class="nounderline abstract_t">Chen YH, Chiou HY, Lin HC, Lin HL. Affect of seizures during gestation on pregnancy outcomes in women with epilepsy. Arch Neurol 2009; 66:979.</a></li><li><a class="nounderline abstract_t">Vinten J, Adab N, Kini U, et al. Neuropsychological effects of exposure to anticonvulsant medication in utero. Neurology 2005; 64:949.</a></li><li><a class="nounderline abstract_t">Sabers A, aRogvi-Hansen B, Dam M, et al. Pregnancy and epilepsy: a retrospective study of 151 pregnancies. Acta Neurol Scand 1998; 97:164.</a></li><li><a class="nounderline abstract_t">Pennell PB, Peng L, Newport DJ, et al. Lamotrigine in pregnancy: clearance, therapeutic drug monitoring, and seizure frequency. Neurology 2008; 70:2130.</a></li><li><a class="nounderline abstract_t">Reisinger TL, Newman M, Loring DW, et al. Antiepileptic drug clearance and seizure frequency during pregnancy in women with epilepsy. Epilepsy Behav 2013; 29:13.</a></li><li><a class="nounderline abstract_t">Petrenaite V, Sabers A, Hansen-Schwartz J. Seizure deterioration in women treated with oxcarbazepine during pregnancy. Epilepsy Res 2009; 84:245.</a></li><li><a class="nounderline abstract_t">Sabers A, Petrenaite V. Seizure frequency in pregnant women treated with lamotrigine monotherapy. Epilepsia 2009; 50:2163.</a></li><li><a class="nounderline abstract_t">Thomas SV, Syam U, Devi JS. Predictors of seizures during pregnancy in women with epilepsy. Epilepsia 2012; 53:e85.</a></li><li><a class="nounderline abstract_t">Pennell PB, French JA, May RC, et al. Changes in Seizure Frequency and Antiepileptic Therapy during Pregnancy. N Engl J Med 2020; 383:2547.</a></li><li><a class="nounderline abstract_t">Pirie DA, Al Wattar BH, Pirie AM, et al. Effects of monitoring strategies on seizures in pregnant women on lamotrigine: a meta-analysis. Eur J Obstet Gynecol Reprod Biol 2014; 172:26.</a></li><li><a class="nounderline abstract_t">Vajda FJ, Hitchcock A, Graham J, et al. Seizure control in antiepileptic drug-treated pregnancy. Epilepsia 2008; 49:172.</a></li><li><a class="nounderline abstract_t">Schmidt D, Canger R, Avanzini G, et al. Change of seizure frequency in pregnant epileptic women. J Neurol Neurosurg Psychiatry 1983; 46:751.</a></li><li><a class="nounderline abstract_t">Otani K. Risk factors for the increased seizure frequency during pregnancy and puerperium. Folia Psychiatr Neurol Jpn 1985; 39:33.</a></li><li><a class="nounderline abstract_t">Bjørk MH, Veiby G, Reiter SC, et al. Depression and anxiety in women with epilepsy during pregnancy and after delivery: a prospective population-based cohort study on frequency, risk factors, medication, and prognosis. Epilepsia 2015; 56:28.</a></li><li><a class="nounderline abstract_t">Kanner AM, Palac S. Depression in epilepsy: a common but often unrecognized comorbid malady. Epilepsy Behav 2000; 1:37.</a></li><li><a class="nounderline abstract_t">Galanti M, Newport DJ, Pennell PB, et al. Postpartum depression in women with epilepsy: influence of antiepileptic drugs in a prospective study. Epilepsy Behav 2009; 16:426.</a></li><li><a class="nounderline abstract_t">Meador KJ, Stowe ZN, Brown C, et al. Prospective Cohort Study of Depression During Pregnancy and the Postpartum Period in Women With Epilepsy vs Control Groups. Neurology 2022; 99:e1573.</a></li><li><a class="nounderline abstract_t">Meador KJ, Cohen MJ, Loring DW, et al. Two-Year-Old Cognitive Outcomes in Children of Pregnant Women With Epilepsy in the Maternal Outcomes and Neurodevelopmental Effects of Antiepileptic Drugs Study. JAMA Neurol 2021; 78:927.</a></li><li><a class="nounderline abstract_t">Meador KJ, Pennell PB, Harden CL, et al. Pregnancy registries in epilepsy: a consensus statement on health outcomes. Neurology 2008; 71:1109.</a></li><li><a class="nounderline abstract_t">Bassi V, Yerby MS, Devinsky O. Epilepsy. Adv Neurol 2002; 90:185.</a></li><li><a class="nounderline abstract_t">Holmes LB, Harvey EA, Coull BA, et al. The teratogenicity of anticonvulsant drugs. N Engl J Med 2001; 344:1132.</a></li><li><a class="nounderline abstract_t">Artama M, Auvinen A, Raudaskoski T, et al. Antiepileptic drug use of women with epilepsy and congenital malformations in offspring. Neurology 2005; 64:1874.</a></li><li><a class="nounderline abstract_t">Morrow J, Russell A, Guthrie E, et al. Malformation risks of antiepileptic drugs in pregnancy: a prospective study from the UK Epilepsy and Pregnancy Register. J Neurol Neurosurg Psychiatry 2006; 77:193.</a></li><li><a class="nounderline abstract_t">Tomson T, Muraca G, Razaz N. Paternal exposure to antiepileptic drugs and offspring outcomes: a nationwide population-based cohort study in Sweden. J Neurol Neurosurg Psychiatry 2020; 91:907.</a></li><li><a class="nounderline abstract_t">Hernández-Díaz S, Werler MM, Walker AM, Mitchell AA. Folic acid antagonists during pregnancy and the risk of birth defects. N Engl J Med 2000; 343:1608.</a></li><li><a class="nounderline abstract_t">Tomson T, Battino D, Bonizzoni E, et al. Dose-dependent risk of malformations with antiepileptic drugs: an analysis of data from the EURAP epilepsy and pregnancy registry. Lancet Neurol 2011; 10:609.</a></li><li><a class="nounderline abstract_t">Tomson T, Battino D, Bonizzoni E, et al. Comparative risk of major congenital malformations with eight different antiepileptic drugs: a prospective cohort study of the EURAP registry. Lancet Neurol 2018; 17:530.</a></li><li><a class="nounderline abstract_t">Samrén EB, van Duijn CM, Christiaens GC, et al. Antiepileptic drug regimens and major congenital abnormalities in the offspring. Ann Neurol 1999; 46:739.</a></li><li><a class="nounderline abstract_t">Meador KJ, Baker GA, Finnell RH, et al. In utero antiepileptic drug exposure: fetal death and malformations. Neurology 2006; 67:407.</a></li><li><a class="nounderline abstract_t">Vajda FJ, Eadie MJ. Maternal valproate dosage and foetal malformations. Acta Neurol Scand 2005; 112:137.</a></li><li><a class="nounderline abstract_t">Vajda FJ, O'Brien TJ, Lander CM, et al. Antiepileptic drug combinations not involving valproate and the risk of fetal malformations. Epilepsia 2016; 57:1048.</a></li><li><a class="nounderline abstract_t">Holmes LB, Mittendorf R, Shen A, et al. Fetal effects of anticonvulsant polytherapies: different risks from different drug combinations. Arch Neurol 2011; 68:1275.</a></li><li><a class="nounderline abstract_t">Shi X, Wang Y, Zhang Y, et al. Effects of antiepileptic drugs polytherapy on pregnancy outcomes in women with epilepsy: An observation study in northwest China. Epilepsy Behav 2022; 135:108904.</a></li><li><a class="nounderline abstract_t">Meador KJ, Pennell PB, May RC, et al. Changes in antiepileptic drug-prescribing patterns in pregnant women with epilepsy. Epilepsy Behav 2018; 84:10.</a></li><li><a class="nounderline abstract_t">Lindhout D, Höppener RJ, Meinardi H. Teratogenicity of antiepileptic drug combinations with special emphasis on epoxidation (of carbamazepine). Epilepsia 1984; 25:77.</a></li><li><a class="nounderline abstract_t">Kaneko S, Battino D, Andermann E, et al. Congenital malformations due to antiepileptic drugs. Epilepsy Res 1999; 33:145.</a></li><li><a class="nounderline abstract_t">Samrén EB, van Duijn CM, Koch S, et al. Maternal use of antiepileptic drugs and the risk of major congenital malformations: a joint European prospective study of human teratogenesis associated with maternal epilepsy. Epilepsia 1997; 38:981.</a></li><li><a class="nounderline abstract_t">Kaaja E, Kaaja R, Hiilesmaa V. Major malformations in offspring of women with epilepsy. Neurology 2003; 60:575.</a></li><li><a class="nounderline abstract_t">Vajda FJ, O'Brien TJ, Lander CM, et al. Teratogenesis in repeated pregnancies in antiepileptic drug-treated women. Epilepsia 2013; 54:181.</a></li><li><a class="nounderline abstract_t">Campbell E, Devenney E, Morrow J, et al. Recurrence risk of congenital malformations in infants exposed to antiepileptic drugs in utero. Epilepsia 2013; 54:165.</a></li><li><a class="nounderline abstract_t">Finnell RH, Buehler BA, Kerr BM, et al. Clinical and experimental studies linking oxidative metabolism to phenytoin-induced teratogenesis. Neurology 1992; 42:25.</a></li><li><a class="nounderline abstract_t">Parman T, Chen G, Wells PG. Free radical intermediates of phenytoin and related teratogens. Prostaglandin H synthase-catalyzed bioactivation, electron paramagnetic resonance spectrometry, and photochemical product analysis. J Biol Chem 1998; 273:25079.</a></li><li><a class="nounderline abstract_t">Hernández-Díaz S, Mittendorf R, Smith CR, et al. Association between topiramate and zonisamide use during pregnancy and low birth weight. Obstet Gynecol 2014; 123:21.</a></li><li><a class="nounderline abstract_t">Veiby G, Daltveit AK, Engelsen BA, Gilhus NE. Fetal growth restriction and birth defects with newer and older antiepileptic drugs during pregnancy. J Neurol 2014; 261:579.</a></li><li><a class="nounderline abstract_t">Gaily E, Kantola-Sorsa E, Granström ML. Specific cognitive dysfunction in children with epileptic mothers. Dev Med Child Neurol 1990; 32:403.</a></li><li><a class="nounderline abstract_t">Thomas SV, Sukumaran S, Lukose N, et al. Intellectual and language functions in children of mothers with epilepsy. Epilepsia 2007; 48:2234.</a></li><li><a class="nounderline abstract_t">Vinten J, Bromley RL, Taylor J, et al. The behavioral consequences of exposure to antiepileptic drugs in utero. Epilepsy Behav 2009; 14:197.</a></li><li><a class="nounderline abstract_t">Oyen N, Vollset SE, Eide MG, et al. Maternal epilepsy and offsprings' adult intelligence: a population-based study from Norway. Epilepsia 2007; 48:1731.</a></li><li><a class="nounderline abstract_t">Forsberg L, Wide K, Källén B. School performance at age 16 in children exposed to antiepileptic drugs in utero--a population-based study. Epilepsia 2011; 52:364.</a></li><li><a class="nounderline abstract_t">Cummings C, Stewart M, Stevenson M, et al. Neurodevelopment of children exposed in utero to lamotrigine, sodium valproate and carbamazepine. Arch Dis Child 2011; 96:643.</a></li><li><a class="nounderline abstract_t">Lacey AS, Pickrell WO, Thomas RH, et al. Educational attainment of children born to mothers with epilepsy. J Neurol Neurosurg Psychiatry 2018; 89:736.</a></li><li><a class="nounderline abstract_t">Bech LF, Polcwiartek C, Kragholm K, et al. In utero exposure to antiepileptic drugs is associated with learning disabilities among offspring. J Neurol Neurosurg Psychiatry 2018; 89:1324.</a></li><li><a class="nounderline abstract_t">Koch S, Titze K, Zimmermann RB, et al. Long-term neuropsychological consequences of maternal epilepsy and anticonvulsant treatment during pregnancy for school-age children and adolescents. Epilepsia 1999; 40:1237.</a></li><li><a class="nounderline abstract_t">Meador KJ, Baker GA, Browning N, et al. Effects of fetal antiepileptic drug exposure: outcomes at age 4.5 years. Neurology 2012; 78:1207.</a></li><li><a class="nounderline abstract_t">Meador KJ, Baker GA, Browning N, et al. Foetal antiepileptic drug exposure and verbal versus non-verbal abilities at three years of age. Brain 2011; 134:396.</a></li><li><a class="nounderline abstract_t">Perucca E, Tomson T. Prenatal exposure to antiepileptic drugs. Lancet 2006; 367:1467.</a></li><li><a class="nounderline abstract_t">Kini U, Adab N, Vinten J, et al. Dysmorphic features: an important clue to the diagnosis and severity of fetal anticonvulsant syndromes. Arch Dis Child Fetal Neonatal Ed 2006; 91:F90.</a></li><li><a class="nounderline abstract_t">Holmes LB, Coull BA, Dorfman J, Rosenberger PB. The correlation of deficits in IQ with midface and digit hypoplasia in children exposed in utero to anticonvulsant drugs. J Pediatr 2005; 146:118.</a></li><li><a class="nounderline abstract_t">Bromfield EB, Dworetzky BA, Wyszynski DF, et al. Valproate teratogenicity and epilepsy syndrome. Epilepsia 2008; 49:2122.</a></li><li><a class="nounderline abstract_t">Koch S, Lösche G, Jager-Romän E, et al. Major and minor birth malformations and antiepileptic drugs. Neurology 1992; 42:83.</a></li><li><a class="nounderline abstract_t">Lindhout D, Omtzigt JG, Cornel MC. Spectrum of neural-tube defects in 34 infants prenatally exposed to antiepileptic drugs. Neurology 1992; 42:111.</a></li><li><a class="nounderline abstract_t">Lindhout D, Schmidt D. In-utero exposure to valproate and neural tube defects. Lancet 1986; 1:1392.</a></li><li><a class="nounderline abstract_t">Tomson T, Battino D. Teratogenic effects of antiepileptic drugs. Lancet Neurol 2012; 11:803.</a></li><li><a class="nounderline abstract_t">Wyszynski DF, Nambisan M, Surve T, et al. Increased rate of major malformations in offspring exposed to valproate during pregnancy. Neurology 2005; 64:961.</a></li><li><a class="nounderline abstract_t">Hernández-Díaz S, Smith CR, Shen A, et al. Comparative safety of antiepileptic drugs during pregnancy. Neurology 2012; 78:1692.</a></li><li><a class="nounderline abstract_t">Jentink J, Loane MA, Dolk H, et al. Valproic acid monotherapy in pregnancy and major congenital malformations. N Engl J Med 2010; 362:2185.</a></li><li><a class="nounderline abstract_t">Vajda FJ, O'Brien TJ, Graham JE, et al. Dose dependence of fetal malformations associated with valproate. Neurology 2013; 81:999.</a></li><li><a class="nounderline abstract_t">Tomson T, Battino D, Bonizzoni E, et al. Dose-dependent teratogenicity of valproate in mono- and polytherapy: an observational study. Neurology 2015; 85:866.</a></li><li><a class="nounderline abstract_t">Bromley RL, Calderbank R, Cheyne CP, et al. Cognition in school-age children exposed to levetiracetam, topiramate, or sodium valproate. Neurology 2016; 87:1943.</a></li><li><a class="nounderline abstract_t">McVearry KM, Gaillard WD, VanMeter J, Meador KJ. A prospective study of cognitive fluency and originality in children exposed in utero to carbamazepine, lamotrigine, or valproate monotherapy. Epilepsy Behav 2009; 16:609.</a></li><li><a class="nounderline abstract_t">Bromley RL, Mawer G, Love J, et al. Early cognitive development in children born to women with epilepsy: a prospective report. Epilepsia 2010; 51:2058.</a></li><li><a class="nounderline abstract_t">Meador KJ, Baker GA, Browning N, et al. Cognitive function at 3 years of age after fetal exposure to antiepileptic drugs. N Engl J Med 2009; 360:1597.</a></li><li><a class="nounderline abstract_t">Gaily E, Kantola-Sorsa E, Hiilesmaa V, et al. Normal intelligence in children with prenatal exposure to carbamazepine. Neurology 2004; 62:28.</a></li><li><a class="nounderline abstract_t">Nadebaum C, Anderson VA, Vajda F, et al. Language skills of school-aged children prenatally exposed to antiepileptic drugs. Neurology 2011; 76:719.</a></li><li><a class="nounderline abstract_t">Thomas SV, Ajaykumar B, Sindhu K, et al. Motor and mental development of infants exposed to antiepileptic drugs in utero. Epilepsy Behav 2008; 13:229.</a></li><li><a class="nounderline abstract_t">Bromley RL, Mawer G, Clayton-Smith J, et al. Autism spectrum disorders following in utero exposure to antiepileptic drugs. Neurology 2008; 71:1923.</a></li><li><a class="nounderline abstract_t">Meador KJ, Baker GA, Browning N, et al. Fetal antiepileptic drug exposure and cognitive outcomes at age 6 years (NEAD study): a prospective observational study. Lancet Neurol 2013; 12:244.</a></li><li><a class="nounderline abstract_t">Bromley R, Weston J, Adab N, et al. Treatment for epilepsy in pregnancy: neurodevelopmental outcomes in the child. Cochrane Database Syst Rev 2014; :CD010236.</a></li><li><a class="nounderline abstract_t">Baker GA, Bromley RL, Briggs M, et al. IQ at 6 years after in utero exposure to antiepileptic drugs: a controlled cohort study. Neurology 2015; 84:382.</a></li><li><a class="nounderline abstract_t">Elkjær LS, Bech BH, Sun Y, et al. Association Between Prenatal Valproate Exposure and Performance on Standardized Language and Mathematics Tests in School-aged Children. JAMA Neurol 2018; 75:663.</a></li><li><a class="nounderline abstract_t">Unnikrishnan G, Jacob NS, Salim S, et al. Enduring language deficits in children of women with epilepsy and the potential role of intrauterine exposure to antiepileptic drugs. Epilepsia 2020; 61:2442.</a></li><li><a class="nounderline abstract_t">Moore SJ, Turnpenny P, Quinn A, et al. A clinical study of 57 children with fetal anticonvulsant syndromes. J Med Genet 2000; 37:489.</a></li><li><a class="nounderline abstract_t">Rasalam AD, Hailey H, Williams JH, et al. Characteristics of fetal anticonvulsant syndrome associated autistic disorder. Dev Med Child Neurol 2005; 47:551.</a></li><li><a class="nounderline abstract_t">Bromley RL, Mawer GE, Briggs M, et al. The prevalence of neurodevelopmental disorders in children prenatally exposed to antiepileptic drugs. J Neurol Neurosurg Psychiatry 2013; 84:637.</a></li><li><a class="nounderline abstract_t">Christensen J, Grønborg TK, Sørensen MJ, et al. Prenatal valproate exposure and risk of autism spectrum disorders and childhood autism. JAMA 2013; 309:1696.</a></li><li><a class="nounderline abstract_t">Bavoux F, Fournier-Perhilou AI, Wood C, et al. Neonatal fibrinogen depletion caused by sodium valproate. Ann Pharmacother 1994; 28:1307.</a></li><li><a class="nounderline abstract_t">Majer RV, Green PJ. Neonatal afibrinogenaemia due to sodium valproate. Lancet 1987; 2:740.</a></li><li><a class="nounderline abstract_t">Campbell E, Kennedy F, Russell A, et al. Malformation risks of antiepileptic drug monotherapies in pregnancy: updated results from the UK and Ireland Epilepsy and Pregnancy Registers. J Neurol Neurosurg Psychiatry 2014; 85:1029.</a></li><li><a class="nounderline abstract_t">Vajda FJE, Graham JE, Hitchcock AA, et al. Antiepileptic drugs and foetal malformation: analysis of 20 years of data in a pregnancy register. Seizure 2019; 65:6.</a></li><li><a class="nounderline abstract_t">Thomas SV, Jeemon P, Pillai R, et al. Malformation risk of new anti-epileptic drugs in women with epilepsy; observational data from the Kerala registry of epilepsy and pregnancy (KREP). Seizure 2021; 93:127.</a></li><li class="breakAll">Gerard EE, Serafini A, Thomas S. Antiseizure medications and structural teratogenesis. In: Epilepsy: A Comprehensive Textbook, 3rd ed, Engel J, Moshe S (Eds), Wolters Kluwer/Lippincott Williams &amp; Wilkins, 2023.</li><li><a class="nounderline abstract_t">Jentink J, Dolk H, Loane MA, et al. Intrauterine exposure to carbamazepine and specific congenital malformations: systematic review and case-control study. BMJ 2010; 341:c6581.</a></li><li><a class="nounderline abstract_t">Rosa FW. Spina bifida in infants of women treated with carbamazepine during pregnancy. N Engl J Med 1991; 324:674.</a></li><li><a class="nounderline abstract_t">Hernández-Díaz S, Werler MM, Walker AM, Mitchell AA. Neural tube defects in relation to use of folic acid antagonists during pregnancy. Am J Epidemiol 2001; 153:961.</a></li><li><a class="nounderline abstract_t">Gerard EE, Meador KJ. An Update on Maternal Use of Antiepileptic Medications in Pregnancy and Neurodevelopment Outcomes. J Pediatr Genet 2015; 4:94.</a></li><li><a class="nounderline abstract_t">Knight R, Wittkowski A, Bromley RL. Neurodevelopmental outcomes in children exposed to newer antiseizure medications: A systematic review. Epilepsia 2021; 62:1765.</a></li><li><a class="nounderline abstract_t">Reinisch JM, Sanders SA, Mortensen EL, Rubin DB. In utero exposure to phenobarbital and intelligence deficits in adult men. JAMA 1995; 274:1518.</a></li><li><a class="nounderline abstract_t">Thorp JA, O'Connor M, Jones AM, et al. Does perinatal phenobarbital exposure affect developmental outcome at age 2? Am J Perinatol 1999; 16:51.</a></li><li><a class="nounderline abstract_t">Mølgaard-Nielsen D, Hviid A. Newer-generation antiepileptic drugs and the risk of major birth defects. JAMA 2011; 305:1996.</a></li><li><a class="nounderline abstract_t">Fujii H, Goel A, Bernard N, et al. Pregnancy outcomes following gabapentin use: results of a prospective comparative cohort study. Neurology 2013; 80:1565.</a></li><li><a class="nounderline abstract_t">Montouris G. Gabapentin exposure in human pregnancy: results from the Gabapentin Pregnancy Registry. Epilepsy Behav 2003; 4:310.</a></li><li class="breakAll">Glaxo SmithKline. The Lamotrigine Pregnancy registry. Interim report: 1 September 1992 through 30 September 2008; Issued January 2008. http://pregnancyregistry.gsk.com/lamotrigine.html (Accessed on March 31, 2008).</li><li><a class="nounderline abstract_t">Cunnington MC, Weil JG, Messenheimer JA, et al. Final results from 18 years of the International Lamotrigine Pregnancy Registry. Neurology 2011; 76:1817.</a></li><li><a class="nounderline abstract_t">Cunnington M, Ferber S, Quartey G, International Lamotrigine Pregnancy Registry Scientific Advisory Committee. Effect of dose on the frequency of major birth defects following fetal exposure to lamotrigine monotherapy in an international observational study. Epilepsia 2007; 48:1207.</a></li><li><a class="nounderline abstract_t">Holmes LB, Baldwin EJ, Smith CR, et al. Increased frequency of isolated cleft palate in infants exposed to lamotrigine during pregnancy. Neurology 2008; 70:2152.</a></li><li><a class="nounderline abstract_t">Dolk H, Jentink J, Loane M, et al. Does lamotrigine use in pregnancy increase orofacial cleft risk relative to other malformations? Neurology 2008; 71:714.</a></li><li><a class="nounderline abstract_t">Dolk H, Wang H, Loane M, et al. Lamotrigine use in pregnancy and risk of orofacial cleft and other congenital anomalies. Neurology 2016; 86:1716.</a></li><li><a class="nounderline abstract_t">Meador KJ, Cohen MJ, Loring DW, et al. Cognitive outcomes at age 3 years in children with fetal exposure to antiseizure medications (MONEAD study) in the USA: a prospective, observational cohort study. Lancet Neurol 2023; 22:712.</a></li><li><a class="nounderline abstract_t">Bromley RL, Bullen P, Campbell E, et al. Neurodevelopment of babies born to mothers with epilepsy: A prospective observational cohort study. Epilepsia 2023; 64:2454.</a></li><li><a class="nounderline abstract_t">Weston J, Bromley R, Jackson CF, et al. Monotherapy treatment of epilepsy in pregnancy: congenital malformation outcomes in the child. Cochrane Database Syst Rev 2016; 11:CD010224.</a></li><li><a class="nounderline abstract_t">Shallcross R, Bromley RL, Irwin B, et al. Child development following in utero exposure: levetiracetam vs sodium valproate. Neurology 2011; 76:383.</a></li><li><a class="nounderline abstract_t">Shallcross R, Bromley RL, Cheyne CP, et al. In utero exposure to levetiracetam vs valproate: development and language at 3 years of age. Neurology 2014; 82:213.</a></li><li><a class="nounderline abstract_t">Dreier JW, Bjørk MH, Alvestad S, et al. Prenatal Exposure to Antiseizure Medication and Incidence of Childhood- and Adolescence-Onset Psychiatric Disorders. JAMA Neurol 2023; 80:568.</a></li><li><a class="nounderline abstract_t">Lindhout D, Meinardi H, Meijer JW, Nau H. Antiepileptic drugs and teratogenesis in two consecutive cohorts: changes in prescription policy paralleled by changes in pattern of malformations. Neurology 1992; 42:94.</a></li><li><a class="nounderline abstract_t">Kaneko S, Otani K, Kondo T, et al. Malformation in infants of mothers with epilepsy receiving antiepileptic drugs. Neurology 1992; 42:68.</a></li><li><a class="nounderline abstract_t">Dravet C, Julian C, Legras C, et al. Epilepsy, antiepileptic drugs, and malformations in children of women with epilepsy: a French prospective cohort study. Neurology 1992; 42:75.</a></li><li><a class="nounderline abstract_t">Holmes LB, Wyszynski DF, Lieberman E. The AED (antiepileptic drug) pregnancy registry: a 6-year experience. Arch Neurol 2004; 61:673.</a></li><li><a class="nounderline abstract_t">Adams J, Janulewicz PA, Macklin EA, et al. Neuropsychological effects in children exposed to anticonvulsant monotherapy during gestation: Phenobarbital, carbamazepine, and phenytoin. Epilepsy Behav 2022; 127:108533.</a></li><li><a class="nounderline abstract_t">Annegers JF, Hauser WA, Elveback LR, et al. Congenital malformations and seizure disorders in the offspring of parents with epilepsy. Int J Epidemiol 1978; 7:241.</a></li><li><a class="nounderline abstract_t">Winterfeld U, Merlob P, Baud D, et al. Pregnancy outcome following maternal exposure to pregabalin may call for concern. Neurology 2016; 86:2251.</a></li><li><a class="nounderline abstract_t">Pennell PB, Meador KJ. A common medication for neuropsychiatric illnesses may cause common problems in pregnancy. Neurology 2016; 86:2224.</a></li><li><a class="nounderline abstract_t">Patorno E, Bateman BT, Huybrechts KF, et al. Pregabalin use early in pregnancy and the risk of major congenital malformations. Neurology 2017; 88:2020.</a></li><li><a class="nounderline abstract_t">Hernandez-Diaz S, Huybrechts KF, Desai RJ, et al. Topiramate use early in pregnancy and the risk of oral clefts: A pregnancy cohort study. Neurology 2018; 90:e342.</a></li><li class="breakAll">FDA Drug Safety Communication: Risk of oral clefts in children born to mothers taking Topamax (topiramate). U.S. Food &amp; Drug Administration, https://www.fda.gov/Drugs/DrugSafety/ucm245085.htm (Accessed on June 25, 2018).</li><li><a class="nounderline abstract_t">Margulis AV, Mitchell AA, Gilboa SM, et al. Use of topiramate in pregnancy and risk of oral clefts. Am J Obstet Gynecol 2012; 207:405.e1.</a></li><li><a class="nounderline abstract_t">Hunt S, Russell A, Smithson WH, et al. Topiramate in pregnancy: preliminary experience from the UK Epilepsy and Pregnancy Register. Neurology 2008; 71:272.</a></li><li class="breakAll">PRAC recommends new measures to avoid topiramate exposure in pregnancy. European Medicines Agency. https://www.ema.europa.eu/en/news/prac-recommends-new-measures-avoid-topiramate-exposure-pregnancy (Accessed on September 13, 2023).</li><li><a class="nounderline abstract_t">McCluskey G, Kinney MO, Russell A, et al. Zonisamide safety in pregnancy: Data from the UK and Ireland epilepsy and pregnancy register. Seizure 2021; 91:311.</a></li><li><a class="nounderline abstract_t">Ottman R, Annegers JF, Hauser WA, Kurland LT. Higher risk of seizures in offspring of mothers than of fathers with epilepsy. Am J Hum Genet 1988; 43:257.</a></li><li><a class="nounderline abstract_t">Holmes GL, Weber DA. Effect of seizures during pregnancy on seizure susceptibility in offspring. Epilepsia 1985; 26:421.</a></li><li><a class="nounderline abstract_t">Schupf N, Ottman R. Risk of epilepsy in offspring of affected women: association with maternal spontaneous abortion. Neurology 2001; 57:1642.</a></li><li><a class="nounderline abstract_t">Tsuboi T, Endo S. Incidence of seizures and EEG abnormalities among offspring of epileptic patients. Hum Genet 1977; 36:173.</a></li><li><a class="nounderline abstract_t">Peljto AL, Barker-Cummings C, Vasoli VM, et al. Familial risk of epilepsy: a population-based study. Brain 2014; 137:795.</a></li><li class="breakAll">Chen MH, Walsh CA. FLNA deficiency. In: GeneReviews®, Adam MP, Mirzaa GM, Pagon RA, et al (Eds), University of Washington, Seattle, Seattle (WA) 1993. https://www.ncbi.nlm.nih.gov/books/NBK1213/ (Accessed on July 26, 2023).</li></ol></div><div id="topicVersionRevision">Topic 2218 Version 50.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26318519" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Epilepsy in pregnancy and reproductive outcomes: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28672292" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Association Between Pregnancy and Perinatal Outcomes Among Women With Epilepsy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26147878" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Mortality and Morbidity During Delivery Hospitalization Among Pregnant Women With Epilepsy in the United States.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14981376" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Epilepsy and pregnancy: an obstetric perspective.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19490036" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Pregnancy, delivery, and outcome for the child in maternal epilepsy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21557799" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Obstetric outcome in women with epilepsy: a hospital-based, retrospective study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19398682" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Practice parameter update: management issues for women with epilepsy--focus on pregnancy (an evidence-based review): obstetrical complications and change in seizure frequency: report of the Quality Standards Subcommittee and Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and American Epilepsy Society.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19398681" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Practice parameter update: management issues for women with epilepsy--focus on pregnancy (an evidence-based review): teratogenesis and perinatal outcomes: report of the Quality Standards Subcommittee and Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and American Epilepsy Society.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19781049" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Complications during pregnancy in women with epilepsy: population-based cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29587185" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Pregnancy outcomes among women with epilepsy: A retrospective cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31806691" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Fetal loss and malformations in the MONEAD study of pregnant women with epilepsy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36912826" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Comparison of Perinatal Outcomes for Women With and Without Epilepsy: A Systematic Review and Meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31782407" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Management of epilepsy in pregnancy: a report from the International League Against Epilepsy Task Force on Women and Pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27512445" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Trends in maternal deaths from epilepsy in the United Kingdom: a 30-year retrospective review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24754364" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : SUDEP and epilepsy-related mortality in pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29710218" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Fertility and Birth Outcomes in Women With Epilepsy Seeking Pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16382034" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Seizure control and treatment in pregnancy: observations from the EURAP epilepsy pregnancy registry.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25150301" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Use of antiepileptic drugs during pregnancy and risk of spontaneous abortion and stillbirth: population based cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28856694" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Fetal growth and premature delivery in pregnant women on antiepileptic drugs.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25231599" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Birth outcomes after prenatal exposure to antiepileptic drugs--a population-based study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35253116" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : The Obstetrical Care and Delivery Experience of Women with Epilepsy in the MONEAD Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/106102" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Fetal heart rate during a maternal grand mal epileptic seizure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9748057" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : A maternal complex partial seizure in labor can affect fetal heart rate.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19667219" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Affect of seizures during gestation on pregnancy outcomes in women with epilepsy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15781806" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Neuropsychological effects of exposure to anticonvulsant medication in utero.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9531432" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Pregnancy and epilepsy: a retrospective study of 151 pregnancies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18046009" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Lamotrigine in pregnancy: clearance, therapeutic drug monitoring, and seizure frequency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23911354" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Antiepileptic drug clearance and seizure frequency during pregnancy in women with epilepsy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19231139" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Seizure deterioration in women treated with oxcarbazepine during pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19490048" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Seizure frequency in pregnant women treated with lamotrigine monotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22429269" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Predictors of seizures during pregnancy in women with epilepsy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33369356" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Changes in Seizure Frequency and Antiepileptic Therapy during Pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24211103" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Effects of monitoring strategies on seizures in pregnant women on lamotrigine: a meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18031551" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Seizure control in antiepileptic drug-treated pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6411866" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Change of seizure frequency in pregnant epileptic women.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4054760" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Risk factors for the increased seizure frequency during pregnancy and puerperium.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25524160" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Depression and anxiety in women with epilepsy during pregnancy and after delivery: a prospective population-based cohort study on frequency, risk factors, medication, and prognosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12609126" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Depression in epilepsy: a common but often unrecognized comorbid malady.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19854113" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Postpartum depression in women with epilepsy: influence of antiepileptic drugs in a prospective study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35977832" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Prospective Cohort Study of Depression During Pregnancy and the Postpartum Period in Women With Epilepsy vs Control Groups.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34096986" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Two-Year-Old Cognitive Outcomes in Children of Pregnant Women With Epilepsy in the Maternal Outcomes and Neurodevelopmental Effects of Antiepileptic Drugs Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18703463" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Pregnancy registries in epilepsy: a consensus statement on health outcomes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12068452" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Epilepsy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11297704" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : The teratogenicity of anticonvulsant drugs.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15955936" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Antiepileptic drug use of women with epilepsy and congenital malformations in offspring.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16157661" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Malformation risks of antiepileptic drugs in pregnancy: a prospective study from the UK Epilepsy and Pregnancy Register.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32651245" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Paternal exposure to antiepileptic drugs and offspring outcomes: a nationwide population-based cohort study in Sweden.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11096168" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Folic acid antagonists during pregnancy and the risk of birth defects.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21652013" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Dose-dependent risk of malformations with antiepileptic drugs: an analysis of data from the EURAP epilepsy and pregnancy registry.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29680205" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Comparative risk of major congenital malformations with eight different antiepileptic drugs: a prospective cohort study of the EURAP registry.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10553991" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Antiepileptic drug regimens and major congenital abnormalities in the offspring.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16894099" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : In utero antiepileptic drug exposure: fetal death and malformations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16097954" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Maternal valproate dosage and foetal malformations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27265509" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Antiepileptic drug combinations not involving valproate and the risk of fetal malformations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21670385" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Fetal effects of anticonvulsant polytherapies: different risks from different drug combinations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36095876" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Effects of antiepileptic drugs polytherapy on pregnancy outcomes in women with epilepsy: An observation study in northwest China.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29730500" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Changes in antiepileptic drug-prescribing patterns in pregnant women with epilepsy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6692794" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Teratogenicity of antiepileptic drug combinations with special emphasis on epoxidation (of carbamazepine).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10094426" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Congenital malformations due to antiepileptic drugs.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9579936" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Maternal use of antiepileptic drugs and the risk of major congenital malformations: a joint European prospective study of human teratogenesis associated with maternal epilepsy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12601095" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Major malformations in offspring of women with epilepsy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22882134" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Teratogenesis in repeated pregnancies in antiepileptic drug-treated women.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23167802" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Recurrence risk of congenital malformations in infants exposed to antiepileptic drugs in utero.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1574173" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Clinical and experimental studies linking oxidative metabolism to phenytoin-induced teratogenesis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9737965" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Free radical intermediates of phenytoin and related teratogens. Prostaglandin H synthase-catalyzed bioactivation, electron paramagnetic resonance spectrometry, and photochemical product analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24463659" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Association between topiramate and zonisamide use during pregnancy and low birth weight.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24449062" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Fetal growth restriction and birth defects with newer and older antiepileptic drugs during pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2113015" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Specific cognitive dysfunction in children with epileptic mothers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17941847" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Intellectual and language functions in children of mothers with epilepsy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18992367" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : The behavioral consequences of exposure to antiepileptic drugs in utero.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17521348" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Maternal epilepsy and offsprings' adult intelligence: a population-based study from Norway.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21054354" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : School performance at age 16 in children exposed to antiepileptic drugs in utero--a population-based study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21415043" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Neurodevelopment of children exposed in utero to lamotrigine, sodium valproate and carbamazepine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29588327" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Educational attainment of children born to mothers with epilepsy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30076271" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : In utero exposure to antiepileptic drugs is associated with learning disabilities among offspring.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10487186" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Long-term neuropsychological consequences of maternal epilepsy and anticonvulsant treatment during pregnancy for school-age children and adolescents.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22491865" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Effects of fetal antiepileptic drug exposure: outcomes at age 4.5 years.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21224309" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Foetal antiepileptic drug exposure and verbal versus non-verbal abilities at three years of age.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16679145" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Prenatal exposure to antiepileptic drugs.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16239295" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Dysmorphic features: an important clue to the diagnosis and severity of fetal anticonvulsant syndromes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15644835" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : The correlation of deficits in IQ with midface and digit hypoplasia in children exposed in utero to anticonvulsant drugs.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18557775" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Valproate teratogenicity and epilepsy syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1574183" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Major and minor birth malformations and antiepileptic drugs.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1574164" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Spectrum of neural-tube defects in 34 infants prenatally exposed to antiepileptic drugs.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2872511" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : In-utero exposure to valproate and neural tube defects.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22805351" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Teratogenic effects of antiepileptic drugs.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15781808" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Increased rate of major malformations in offspring exposed to valproate during pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22551726" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Comparative safety of antiepileptic drugs during pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20558369" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Valproic acid monotherapy in pregnancy and major congenital malformations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23911758" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : Dose dependence of fetal malformations associated with valproate.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26085607" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : Dose-dependent teratogenicity of valproate in mono- and polytherapy: an observational study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27581218" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : Cognition in school-age children exposed to levetiracetam, topiramate, or sodium valproate.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19892603" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : A prospective study of cognitive fluency and originality in children exposed in utero to carbamazepine, lamotrigine, or valproate monotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20633039" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : Early cognitive development in children born to women with epilepsy: a prospective report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19369666" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : Cognitive function at 3 years of age after fetal exposure to antiepileptic drugs.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14718692" id="rid95" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>96 : Normal intelligence in children with prenatal exposure to carbamazepine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21339499" id="rid96" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>97 : Language skills of school-aged children prenatally exposed to antiepileptic drugs.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18346940" id="rid97" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>98 : Motor and mental development of infants exposed to antiepileptic drugs in utero.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19047565" id="rid98" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>99 : Autism spectrum disorders following in utero exposure to antiepileptic drugs.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23352199" id="rid99" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>100 : Fetal antiepileptic drug exposure and cognitive outcomes at age 6 years (NEAD study): a prospective observational study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25354543" id="rid100" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>101 : Treatment for epilepsy in pregnancy: neurodevelopmental outcomes in the child.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25540307" id="rid101" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>102 : IQ at 6 years after in utero exposure to antiepileptic drugs: a controlled cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29459981" id="rid102" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>103 : Association Between Prenatal Valproate Exposure and Performance on Standardized Language and Mathematics Tests in School-aged Children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33345345" id="rid103" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>104 : Enduring language deficits in children of women with epilepsy and the potential role of intrauterine exposure to antiepileptic drugs.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10882750" id="rid104" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>105 : A clinical study of 57 children with fetal anticonvulsant syndromes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16108456" id="rid105" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>106 : Characteristics of fetal anticonvulsant syndrome associated autistic disorder.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23370617" id="rid106" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>107 : The prevalence of neurodevelopmental disorders in children prenatally exposed to antiepileptic drugs.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23613074" id="rid107" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>108 : Prenatal valproate exposure and risk of autism spectrum disorders and childhood autism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7849355" id="rid108" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>109 : Neonatal fibrinogen depletion caused by sodium valproate.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2888962" id="rid109" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>110 : Neonatal afibrinogenaemia due to sodium valproate.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24444855" id="rid110" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>111 : Malformation risks of antiepileptic drug monotherapies in pregnancy: updated results from the UK and Ireland Epilepsy and Pregnancy Registers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30593875" id="rid111" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>112 : Antiepileptic drugs and foetal malformation: analysis of 20 years of data in a pregnancy register.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34740142" id="rid112" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>113 : Malformation risk of new anti-epileptic drugs in women with epilepsy; observational data from the Kerala registry of epilepsy and pregnancy (KREP).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34740142" id="rid113" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>114 : Malformation risk of new anti-epileptic drugs in women with epilepsy; observational data from the Kerala registry of epilepsy and pregnancy (KREP).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21127116" id="rid114" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>115 : Intrauterine exposure to carbamazepine and specific congenital malformations: systematic review and case-control study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1994251" id="rid115" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>116 : Spina bifida in infants of women treated with carbamazepine during pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11384952" id="rid116" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>117 : Neural tube defects in relation to use of folic acid antagonists during pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27617120" id="rid117" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>118 : An Update on Maternal Use of Antiepileptic Medications in Pregnancy and Neurodevelopment Outcomes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34128227" id="rid118" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>119 : Neurodevelopmental outcomes in children exposed to newer antiseizure medications: A systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7474220" id="rid119" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>120 : In utero exposure to phenobarbital and intelligence deficits in adult men.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10355910" id="rid120" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>121 : Does perinatal phenobarbital exposure affect developmental outcome at age 2?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21586715" id="rid121" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>122 : Newer-generation antiepileptic drugs and the risk of major birth defects.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23553472" id="rid122" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>123 : Pregnancy outcomes following gabapentin use: results of a prospective comparative cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12791334" id="rid123" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>124 : Gabapentin exposure in human pregnancy: results from the Gabapentin Pregnancy Registry.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12791334" id="rid124" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>125 : Gabapentin exposure in human pregnancy: results from the Gabapentin Pregnancy Registry.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21606453" id="rid125" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>126 : Final results from 18 years of the International Lamotrigine Pregnancy Registry.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17381445" id="rid126" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>127 : Effect of dose on the frequency of major birth defects following fetal exposure to lamotrigine monotherapy in an international observational study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18448870" id="rid127" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>128 : Increased frequency of isolated cleft palate in infants exposed to lamotrigine during pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18650491" id="rid128" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>129 : Does lamotrigine use in pregnancy increase orofacial cleft risk relative to other malformations?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27053714" id="rid129" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>130 : Lamotrigine use in pregnancy and risk of orofacial cleft and other congenital anomalies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37479375" id="rid130" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>131 : Cognitive outcomes at age 3 years in children with fetal exposure to antiseizure medications (MONEAD study) in the USA: a prospective, observational cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37403560" id="rid131" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>132 : Neurodevelopment of babies born to mothers with epilepsy: A prospective observational cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27819746" id="rid132" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>133 : Monotherapy treatment of epilepsy in pregnancy: congenital malformation outcomes in the child.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21263139" id="rid133" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>134 : Child development following in utero exposure: levetiracetam vs sodium valproate.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24401687" id="rid134" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>135 : In utero exposure to levetiracetam vs valproate: development and language at 3 years of age.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37067807" id="rid135" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>136 : Prenatal Exposure to Antiseizure Medication and Incidence of Childhood- and Adolescence-Onset Psychiatric Disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1574185" id="rid136" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>137 : Antiepileptic drugs and teratogenesis in two consecutive cohorts: changes in prescription policy paralleled by changes in pattern of malformations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1574179" id="rid137" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>138 : Malformation in infants of mothers with epilepsy receiving antiepileptic drugs.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1574181" id="rid138" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>139 : Epilepsy, antiepileptic drugs, and malformations in children of women with epilepsy: a French prospective cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15148143" id="rid139" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>140 : The AED (antiepileptic drug) pregnancy registry: a 6-year experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35042158" id="rid140" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>141 : Neuropsychological effects in children exposed to anticonvulsant monotherapy during gestation: Phenobarbital, carbamazepine, and phenytoin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/721359" id="rid141" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>142 : Congenital malformations and seizure disorders in the offspring of parents with epilepsy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27194385" id="rid142" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>143 : Pregnancy outcome following maternal exposure to pregabalin may call for concern.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27194382" id="rid143" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>144 : A common medication for neuropsychiatric illnesses may cause common problems in pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28446648" id="rid144" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>145 : Pregabalin use early in pregnancy and the risk of major congenital malformations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29282333" id="rid145" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>146 : Topiramate use early in pregnancy and the risk of oral clefts: A pregnancy cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29282333" id="rid146" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>147 : Topiramate use early in pregnancy and the risk of oral clefts: A pregnancy cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22917484" id="rid147" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>148 : Use of topiramate in pregnancy and risk of oral clefts.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18645165" id="rid148" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>149 : Topiramate in pregnancy: preliminary experience from the UK Epilepsy and Pregnancy Register.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18645165" id="rid149" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>150 : Topiramate in pregnancy: preliminary experience from the UK Epilepsy and Pregnancy Register.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34273670" id="rid150" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>151 : Zonisamide safety in pregnancy: Data from the UK and Ireland epilepsy and pregnancy register.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3414683" id="rid151" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>152 : Higher risk of seizures in offspring of mothers than of fathers with epilepsy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3840086" id="rid152" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>153 : Effect of seizures during pregnancy on seizure susceptibility in offspring.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11706105" id="rid153" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>154 : Risk of epilepsy in offspring of affected women: association with maternal spontaneous abortion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/404230" id="rid154" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>155 : Incidence of seizures and EEG abnormalities among offspring of epileptic patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24468822" id="rid155" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>156 : Familial risk of epilepsy: a population-based study.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
